Manufacturing of anti-BCMA CAR T cells

A 5-7 day T cell manufacturing process using PI3K inhibitors enriches anti-BCMA CAR T cells with markers like CD27+, LEF1+, CCR7+, and TCF1+, addressing the limitations of current methods by enhancing T cell potency and persistence for effective therapeutic applications.

JP7584437B2Active Publication Date: 2024-11-152SEVENTY BIO INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2021560212
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-12-06
Filing Date
2020-04-02
Publication Date
2024-11-15
Estimated Expiration
2040-04-02

AI Technical Summary

Technical Problem

Current methods for producing therapeutic doses of T cells, including engineered T cells, are cumbersome, expensive, and result in short-lived effects with substantial T cell differentiation and lack of persistence, leading to exhaustion of effector immune cell function.

Method used

A 5-7 day T cell manufacturing process using PI3K inhibitors to produce anti-BCMA CAR T cells, enriching populations with markers such as CD27+, LEF1+, CCR7+, and TCF1+, resulting in more potent and durable T cell therapies.

Benefits of technology

The process enhances T cell potency and persistence, allowing for reduced cell doses while maintaining treatment efficacy by enriching for central memory T cells (TCM) and stem cell memory T cells (TSCM) with improved immune effector function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584437000002
    Figure 0007584437000002
  • Figure 0007584437000003
    Figure 0007584437000003
  • Figure 0007584437000004
    Figure 0007584437000004
Patent Text Reader

Abstract

The present invention provides improved anti-BCMA CAR T cell compositions and methods for the production of anti-BCMA CAR T cell therapeutics. More particularly, the present invention relates to improved methods for producing anti-BCMA CAR T cells, resulting in more potent, durable, and effective adoptive T cell immunotherapy. In certain embodiments, the cells are produced from subjects with multiple myeloma or lymphoma.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Application No. 62 / 944,485, filed December 6, 2019, and U.S. Provisional Application No. 62 / 830,004, filed April 5, 2019, which are incorporated by reference in their entireties.

[0002] SEQUENCE LISTING STATEMENT The sequence listing for this application is submitted in text format instead of paper and is incorporated herein by reference. The name of the text file containing the sequence listing is BLBD_118_02WO_ST25.txt. The text file is 7KB, was created on March 27, 2020, and will be submitted electronically via EFS-Web simultaneously with the filing of this application.

[0003] The present invention relates to improved anti-BCMA CAR T cell compositions and methods for the production of anti-BCMA CAR T cells. More particularly, the present invention relates to improved methods for the production of anti-BCMA CAR T cells, resulting in more potent, durable and effective adoptive T cell immunotherapy.

[0004] Description of related fields Adoptive immunotherapy involves the transfer of T lymphocytes to a subject to provide therapy for a disease. Adoptive immunotherapy has yet to realize its potential for treating a wide range of diseases, including cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immune deficiencies. However, not all adoptive immunotherapy strategies require a T cell activation and expansion step to generate a clinically effective therapeutic dose of T cells, although many do. Current techniques for generating therapeutic doses of T cells, including engineered T cells, are limited by cumbersome T cell manufacturing processes. For example, T cell expansion often requires labor-intensive and expensive cloning, and / or multiple rounds of activation / expansion to achieve therapeutically relevant T cell numbers. Furthermore, existing T cell activation / expansion methods are usually coupled with substantial T cell differentiation, which usually results in short-lived effects, including short-lived survival and lack of persistence, as well as lack of in vivo expansion of transferred T cells. Although more recent manufacturing methods have resulted in more potent and persistent T cells, these cells are still prone to exhaustion and loss of effector immune cell functions.

[0005] There remains an unmet need for improvements in T cell manufacturing and more potent and durable T cell therapies. Summary of the Invention

[0006] The present invention generally provides adoptive T cell immunotherapies with improved potency and durability, and methods of making the same.

[0007] In various embodiments, at least 10% CD27 + Provided are cGMP manufactured populations of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, including anti-BCMA CAR T cells.

[0008] In certain embodiments, the population comprises at least 15% CD27 + Includes anti-BCMA CAR T cells.

[0009] In certain embodiments, the population comprises at least 20% CD27 + Includes anti-BCMA CAR T cells.

[0010] In some embodiments, the population is at least 25% CD27 + Includes anti-BCMA CAR T cells.

[0011] In some embodiments, the population is at least 30% CD27 + Includes anti-BCMA CAR T cells.

[0012] In certain embodiments, CD27 + Anti-BCMA CAR T cells are LEF1 + and / or TCF1 + These are anti-BCMA CAR T cells.

[0013] In a further embodiment, CD27 + Anti-BCMA CAR T cells are LEF1 + and TCF1 + Anti-BCMA CAR T cells. In various embodiments, the cGMP manufactured population of anti-BCMA CAR T cells contains at least 10% LEF1 + and / or CCR7 + and TCF1 + Includes anti-BCMA CAR T cells.

[0014] In some embodiments, the population comprises at least 15% LEF1 + and / or CCR7 + and TCF1 + Includes anti-BCMA CAR T cells.

[0015] In some embodiments, the population comprises at least 20% LEF1 + and / or CCR7 + and TCF1 + Includes anti-BCMA CAR T cells.

[0016] In some embodiments, the population comprises at least 25% LEF1 + and / or CCR7 + and TCF1 + Including anti-BCMA CAR T cells.

[0017] In a further embodiment, the population comprises at least 30% LEF1 + and / or CCR7 + and TCF1 + Includes anti-BCMA CAR T cells.

[0018] In a further embodiment, LEF1 + and / or CCR7 + and / or TCF1 + Anti-BCMA CAR T cells express CD27 + These are anti-BCMA CAR T cells.

[0019] In some embodiments, LEF1 + and / or CCR7 + and / or TCF1 + Anti-BCMA CAR T cells are LEF1 + CCR7 + TCF1 + CD27 + These are anti-BCMA CAR T cells.

[0020] In some embodiments, CD27 + and / or LEF1 + and / or CCR7 + and TCF1 + Anti-BCMA CAR T cells are CD4 + Includes anti-BCMA CAR T cells.

[0021] In certain embodiments, CD27 + and / or LEF1 + and / or CCR7 + and TCF1 + Anti-BCMA CAR T cells are CD8 + Includes anti-BCMA CAR T cells.

[0022] In certain embodiments, CD27 + and / or LEF1 + and / or CCR7 + and TCF1 + Anti-BCMA CAR T cells are CD4 + and CD8 + Includes anti-BCMA CAR T cells.

[0023] In certain embodiments, the cells are prepared from a subject with multiple myeloma or lymphoma.

[0024] In certain embodiments, the cells were prepared from a subject with relapsed / refractory multiple myeloma.

[0025] In some embodiments, the cells comprise a lentivirus comprising a polynucleotide encoding an anti-BCMA CAR.

[0026] In a particular embodiment, the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1.

[0027] In a further embodiment, the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2.

[0028] In certain embodiments, the cells are autologous.

[0029] In certain embodiments, the cells are cryopreserved.

[0030] In certain embodiments, the cells are formulated for administration to a subject with multiple myeloma or lymphoma.

[0031] In some embodiments, human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are provided that have been contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, and gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold or at least 2-fold greater in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0032] In certain embodiments, human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are provided that have been contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, and gene expression of one, two, three, four, five, six, seven, eight, nine, or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1 is at least 1.5-fold or at least 2-fold less in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0033] In a further embodiment, human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are provided that have been contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, and have at least 1.5 or at least 2-fold greater gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, and (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR1, IL-1A, and / or (ii) IL-1B, IL-1C, and / or (iii) IL-1B, IL-1C, IL-1D, and / or (iv) IL-1D, IL-1E, IL-1F, IL-1G, IL-1H, IL-1I, and / or (v) IL-1I, IL-1I, IL-1H, and / or (vi) IL-1I, IL-1I, IL-1I, and / or (v) IL-1A, IL-1B, IL-1C, IL-1I, IL-1H, IL-1I, and / or (v) IL-1A, IL-1B, IL-1C, IL-1D, IL-1H, IL-1I, IL-1A, IL-1B, IL-1C, IL-1D, IL-1C, IL-1D, IL-1D, IL-1C, IL-1D, IL-1D, IL-1 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 gene expression is at least 1.5-fold or at least 2-fold less.

[0034] In certain embodiments, CD4 + Anti-BCMA CAR T cells have a central memory T cell (TCM)-like phenotype.

[0035] In a further embodiment, CD8 + Anti-BCMA CAR T cells have a stem cell memory T cell (TSCM)-like phenotype.

[0036] In certain embodiments, CD4 + Anti-BCMA CAR T cells have a TCM-like phenotype and are CD8 + Anti-BCMA CAR T cells have a TSCM-like phenotype.

[0037] In some embodiments, the cells are prepared from a subject with multiple myeloma or lymphoma.

[0038] In certain embodiments, the cells were prepared from a subject with relapsed / refractory multiple myeloma.

[0039] In certain embodiments, the cell comprises a lentivirus comprising a polynucleotide encoding an anti-BCMA CAR.

[0040] In a particular embodiment, the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1.

[0041] In a particular embodiment, the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2.

[0042] In certain embodiments, the cells are autologous.

[0043] In certain embodiments, the cells are cryopreserved.

[0044] In certain embodiments, the cells are formulated for administration to a subject with multiple myeloma or lymphoma.

[0045] In a further embodiment, the PI3K inhibitor is ZSTK474.

[0046] In certain embodiments, a pharmaceutical composition is provided comprising a physiologically acceptable excipient and a therapeutically effective amount of anti-BCMA CAR T cells as contemplated herein.

[0047] In some embodiments, a therapeutically effective amount of anti-BCMA CAR T cells is at least about 5.0×10 7 anti-BCMA CAR T cells.

[0048] In a specific embodiment, a therapeutically effective amount of anti-BCMA CAR T cells is at least about 15.0 x 10 7 anti-BCMA CAR T cells.

[0049] In certain embodiments, a therapeutically effective amount is at least about 45.0×10 7 anti-BCMA CAR T cells.

[0050] In certain embodiments, a therapeutically effective amount is at least about 80.0×10 7 anti-BCMA CAR T cells.

[0051] In a further embodiment, the composition is formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.

[0052] In certain embodiments, methods are provided for treating a subject having multiple myeloma or lymphoma with the compositions contemplated herein.

[0053] In certain embodiments, the subject has relapsed / refractory multiple myeloma.

[0054] In various embodiments, a method of producing anti-BCMA CAR T cells is provided, comprising activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1, and culturing and expanding the transduced T cells for about 5 to about 7 days, wherein the foregoing steps are performed in the presence of a PI3K inhibitor, and wherein gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold or at least 2-fold greater in the cultured T cells compared to T cells transduced with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1 and cultured and expanded for about 10 days.

[0055] In certain embodiments, a method of producing anti-BCMA CAR T cells is provided, comprising activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1, culturing and expanding the transduced T cells for about 5 to about 7 days, wherein the foregoing steps are performed in the presence of a PI3K inhibitor, and wherein gene expression of one, two, three, four, five, six, seven, eight, nine, or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5-fold or at least 2-fold less in the cultured T cells compared to T cells transduced with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1 and cultured and expanded for about 10 days.

[0056] In various embodiments, a method of producing anti-BCMA CAR T cells is provided, comprising activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1, and culturing and expanding the transduced T cells for about 5 to about 7 days, wherein the foregoing steps are performed in the presence of a PI3K inhibitor, and wherein the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1. Gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold or at least 2-fold greater, and gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1 is at least 1.5-fold or at least 2-fold less, in the cultured T cells compared to T cells transduced with a lentiviral vector encoding a CAR and cultured and expanded for about 10 days.

[0057] In various embodiments, a method of producing anti-BCMA CAR T cells is provided, comprising activating a T cell population and stimulating the T cell population to expand; transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1; culturing and expanding the transduced T cells for about 5 to about 7 days, wherein the aforementioned steps are performed in the presence of a PI3K inhibitor, and the expanded cells express CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + It is.

[0058] In a specific embodiment, the anti-BCMA CAR T cells have at least 10% CD27 + and / or LEF1+ and / or CCR7 + and / or TCF1 + Includes T cells.

[0059] In a further embodiment, the anti-BCMA CAR T cells have at least 15% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0060] In some embodiments, the anti-BCMA CAR T cells have at least 20% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0061] In some embodiments, the anti-BCMA CAR T cells have at least 25% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0062] In a specific embodiment, the anti-BCMA CAR T cells have at least 30% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0063] In a further embodiment, CD27 + Cells are LEF1 + and / or CCR7 + and / or TCF1 + It is.

[0064] In a further embodiment, CD27 + Cells are LEF1 + , CCR7 + , and TCF1+ It is.

[0065] In certain embodiments, CD27 + and / or LEF1 + and / or CCR7 + and TCF1 + Anti-BCMA CAR T cells are CD4 + Includes anti-BCMA CAR T cells.

[0066] In certain embodiments, CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Anti-BCMA CAR T cells are CD8 + Includes anti-BCMA CAR T cells.

[0067] In a further embodiment, CD27 + and / or LEF1 + and / or CCR7 + and TCF1 + Anti-BCMA CAR T cells are CD4 + and CD8 + Includes anti-BCMA CAR T cells.

[0068] In certain embodiments, the T cells are autologous.

[0069] In an additional embodiment, the method further comprises isolating peripheral blood mononuclear cells (PBMCs) as a source of T cells.

[0070] In some embodiments, PBMCs are isolated from a subject with multiple myeloma or lymphoma.

[0071] In certain embodiments, the subject has relapsed / refractory multiple myeloma.

[0072] In certain embodiments, the method further comprises cryopreserving the PBMCs prior to activation and stimulation.

[0073] In a further embodiment, the T cells are cryopreserved expanded cultures.

[0074] In a further embodiment, the T cells are activated and simulated to proliferate for about 18 to about 24 hours.

[0075] In certain embodiments, activating the T cell comprises contacting the T cell with an anti-CD3 antibody or antigen-binding fragment thereof.

[0076] In certain embodiments, the anti-CD3 antibody or antigen-binding fragment thereof is soluble.

[0077] In additional embodiments, the anti-CD3 antibody or antigen-binding fragment thereof is bound to a surface.

[0078] In some embodiments, the surface is a bead, optionally a paramagnetic bead.

[0079] In a further embodiment, stimulating the T cell comprises contacting the T cell with an anti-CD28 antibody, or antigen-binding fragment thereof.

[0080] In certain embodiments, the anti-CD28 antibody or antigen-binding fragment thereof is soluble.

[0081] In additional embodiments, the anti-CD28 antibody or antigen-binding fragment thereof is bound to a surface.

[0082] In some embodiments, the surface is a bead, optionally a paramagnetic bead, optionally a paramagnetic bead that is coupled to an anti-CD3 antibody or antigen-binding fragment thereof.

[0083] In certain embodiments, the cells are transduced with an HIV-1 derived lentiviral vector.

[0084] In some embodiments, the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2.

[0085] In a further embodiment, the PI3K inhibitor is ZSTK474.

[0086] In various embodiments, in adoptive cell therapy, CD4 + TCM-like anti-BCMA CAR T cells and CD8 + A method for expanding TSCM-like anti-BCMA CAR T cells is provided, comprising ex vivo contacting the anti-BCMA CAR T cells with a PI3K inhibitor for about 5 to about 7 days, and + TCM-like anti-BCMA CAR T cells and CD8 + The number of TSCM-like anti-BCMA CAR T cells was at least two-fold higher in anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with a PI3K inhibitor for approximately 10 days.

[0087] In a specific embodiment, the anti-BCMA CAR T cells have at least 10% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0088] In a further embodiment, the anti-BCMA CAR T cells have at least 15% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0089] In some embodiments, the anti-BCMA CAR T cells have at least 20% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0090] In a specific embodiment, the anti-BCMA CAR T cells have at least 25% CD27 +and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0091] In a further embodiment, the anti-BCMA CAR T cells have at least 30% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Includes T cells.

[0092] In certain embodiments, the T cells are autologous.

[0093] In certain embodiments, the method further comprises isolating peripheral blood mononuclear cells (PBMCs) as a source of T cells.

[0094] In additional embodiments, PBMCs are isolated from a subject with multiple myeloma or lymphoma.

[0095] In some embodiments, the subject has relapsed / refractory multiple myeloma.

[0096] In a further embodiment, the anti-BCMA CAR T cells comprise an HIV-1 derived lentiviral vector.

[0097] In a particular embodiment, the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1.

[0098] In a further embodiment, the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2.

[0099] In some embodiments, a pharmaceutical composition is provided comprising a pharma- ceutically acceptable excipient and a therapeutically effective amount of anti-BCMA CAR T cells as contemplated herein.

[0100] In some embodiments, a pharma- ceutically acceptable excipient and a therapeutically effective amount of CD4 + TCM anti-BCMA CAR T cells and CD8 + Pharmaceutical compositions comprising TSCM anti-BCMA CAR T cells are provided.

[0101] In certain embodiments, a method of treating a subject having multiple myeloma or lymphoma comprises administering a composition contemplated herein.

[0102] In a further embodiment, the subject has relapsed / refractory multiple myeloma.

[0103] In various embodiments, a method is provided for increasing gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B in anti-BCMA CAR T cells, comprising contacting the anti-BCMA CAR T cells with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5 fold greater in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0104] In certain embodiments, a method is provided for reducing gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 in anti-BCMA CAR T cells, comprising contacting the anti-BCMA CAR T cells with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5-fold less in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0105] In certain embodiments, a method is provided for increasing gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, and decreasing gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1, in anti-BCMA CAR T cells, comprising contacting the anti-BCMA CAR T cells ex vivo with a PI3K inhibitor for about 5 to about 7 days, wherein the anti-BCMA CAR T cells are more potent than anti-BCMA CAR T cells contacted ex vivo with a PI3K inhibitor for about 10 days. In T cells, gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold greater, and gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1 is at least 1.5-fold less.

[0106] In some embodiments, a method of increasing the therapeutic efficacy of anti-BCMA CAR T cells is provided, comprising contacting the anti-BCMA CAR T cells ex vivo with a PI3K inhibitor for about 5 to about 7 days, wherein the increased therapeutic efficacy is indicated by an increase in gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5; or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B that is at least 1.5 fold greater in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0107] In certain embodiments, a method of increasing the therapeutic efficacy of anti-BCMA CAR T cells is provided, comprising contacting the anti-BCMA CAR T cells ex vivo with a PI3K inhibitor for about 5 to about 7 days, wherein the increased therapeutic efficacy is indicated by a decrease in gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1 that is at least 1.5-fold less in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days.

[0108] In some embodiments, a method of increasing the therapeutic efficacy of anti-BCMA CAR T cells is provided, comprising contacting anti-BCMA CAR T cells ex vivo with a PI3K inhibitor for about 5 to about 7 days, wherein the increased therapeutic efficacy is at least a 1.5-fold increase in gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5; or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B; and (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22 , as indicated by at least a 1.5-fold reduction in gene expression of ILDR2 , ATAD3 , NKD2 and WDR62 or (ii) NKD2 and NQO1 , respectively.

[0109] In certain embodiments, the anti-BCMA CAR T cells are derived from a subject with multiple myeloma or lymphoma.

[0110] In an additional embodiment, the anti-BCMA CAR T cells are derived from a subject with relapsed / refractory multiple myeloma.

[0111] In certain embodiments, the anti-BCMA CAR T cells comprise an HIV-1 derived lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR.

[0112] In a particular embodiment, the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1.

[0113] In a further embodiment, the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2.

[0114] In some embodiments, the anti-BCMA CAR T cells are autologous.

[0115] In a particular embodiment, the PI3K inhibitor is ZSTK474. [Brief description of the drawings]

[0116] [Figure 1] Figure 1 shows that the length of T cell culture with PI3K inhibitors modulates T cell phenotype. Five multiple myeloma PBMC lots were used to manufacture anti-BCMA CAR T cells in the absence of PI3K inhibitors or cultured with PI3K inhibitors for 7 or 10 days after transduction with lentivirus encoding anti-BCMA CAR. On days 7 and 10, T cells were stained with anti-human antibodies against CD3, CD62L, CCR7, and CD45RA and analyzed by flow cytometry. Each dot plot was gated on viable CD3+ lymphocytes. [Diagram 2] Figure 2 shows that T cells exhibit a more potent phenotype after 7 days of culture with PI3K inhibitors compared to 10 days of culture. Five multiple myeloma PBMC lots were used to produce anti-BCMA CAR T cells in the presence of PI3K inhibitors for 7 or 10 days. On days 7 and 10, T cells were stained with anti-human antibodies against CCR7, CD25, CD28, CD122, ICOS, CD45RO, CD57, and TIM3 and analyzed by CyTOF. Each dot plot was gated on viable CD3+ lymphocytes. [Diagram 3] Figure 3 shows that T cells produced in PI3K inhibitor for 7 days are enriched for CD27+ T cells. Five multiple myeloma PBMC lots were used to produce anti-BCMA CAR T cells in the presence of PI3K inhibitor. On days 7 and 10, T cells were stained with anti-human antibodies against CD4, CD8, and CD27 and analyzed by CyTOF. VISNE plot shows CD27 gated expression in different cell populations. [Figure 4A]Figure 4A-B shows that T cells display a more potent phenotype after 7 days of culture with PI3K inhibitors compared to 10 days of culture. Five multiple myeloma PBMC lots were used to produce anti-BCMA CAR T cells in the presence of PI3K inhibitors for 7 or 10 days. On days 7 and 10, T cells were stained with anti-human antibodies against (1) CCR7, CD25, CD28, HLA-DR, and TIM3 (Figure 4A) or CD45RO, CD57, CD70, CD244, and PD-1 (Figure 4B) and analyzed by CyTOF. VISNE plots show the expression of different T cell phenotypic markers at 7 days of culture (top row) and 10 days of culture (bottom row). Gated populations represent CD27+ cells. [Figure 4B] Same as above. [Diagram 5] Figure 5 shows that CD27+ T cells produced for 10 days in PI3K inhibitors are characterized by decreased activation and increased exhaustion compared to T cells produced for 7 days in PI3K inhibitors. Five multiple myeloma PBMC lots were used to produce anti-BCMA CAR T cells for 7 or 10 days in the presence of PI3K inhibitors. CD27+ T cells identified by VISNE analysis were stained on days 7 and 10 with anti-human antibodies against CD28, ICOS, HLA-DR, CD25, and TIM3 and analyzed by CyTOF in CD4+ T cells (top) and CD8+ T cells (bottom). [Figure 6] Figure 6 shows differential gene expression as a result of duration of anti-BCMA CAR T cell manufacturing. Multiple myeloma PBMC lots were used to manufacture anti-BCMA CAR T cells for 7 days (1) or 10 days (13) in the absence of a PI3K inhibitor, or for 7 days (10) or 10 days (6) in the presence of a PI3K inhibitor. RNA was extracted from the T cells and transcriptional profiles were analyzed using a Nanostring immunology panel. A heatmap of the top 50 differentially expressed genes between manufacturing conditions is shown. [Figure 7]Figure 7 shows the increased potency of anti-BCMA CAR T cells produced for 7 days on a PI3K inhibitor compared to anti-BCMA CAR T cells produced for 10 days on a PI3K inhibitor. PBMCs from healthy donors were activated, transduced with lentiviral vectors encoding anti-BCMA CARs, and expanded for 6 days (7-day process) or 9 days (10-day process) in the presence of IL-2 and a PI3K inhibitor. Ten days prior to adoptive cell therapy, NSG mice were intravenously injected with 2 x 106 firefly luciferase-labeled Daudi tumor cells. Mice were injected with 2.5, 5, or 10 x 106 anti-BCMA CAR+ T cells, or T cells transduced with vehicle. Tumor burden was monitored by luminescence. [Figure 8] Figure 8 shows that T cells produced in the presence of PI3K are enriched for CD27+CD4+TCM-like cells and CD27+CD8+TSCM-like cells. Anti-BCMA CAR T cells produced from multiple myeloma PBMC lots in the presence of PI3K inhibitors were stained with a panel of approximately 36 T cell phenotype antibodies and analyzed by CyTOF. Naive T cells (Tnaive), central memory T cells (TCM), effector memory T cells (EM), effector T cells (TEff), and stem cell memory T cells (TSCM) are shown. Data presented shows each DP lot analyzed as a function of % of CD27+ enriched cells relative to T cell subsets. [Figure 9] Figure 9 shows the CD8+ T cell data from Figure 9 analyzed using FlowSOM. FlowSOM identified 20 distinct T cell clusters. Three major groups of T cells were identified based on cluster 4 (enriched for memory T cell markers - good) and cluster 5 (enriched for effector T cell markers - bad). The %CD27+CD8+ T cells, manufacturing method, and clinical response of subjects treated with anti-BCMA CAR T cells are shown. [Figure 10]Figure 10 shows differential gene expression analysis of anti-BCMA CAR T cells manufactured from multiple myeloma cell lots using the 7-day or 10-day PI3K manufacturing process. RNA was extracted from 12 lots of anti-BCMA CAR T cells and transcriptional profiles were analyzed using a Nanostring immunology panel. A heat map of the top 25 differentially expressed genes between the 7-day and 10-day manufacturing processes is shown. The %CD27+ cells, manufacturing method, and clinical response of subjects treated with anti-BCMA CAR T cells are shown. [Figure 11] Figure 11A shows a volcano plot of cyTOF stained T cell populations in anti-BCMA CAR T cell medicines in sustained responders compared to non-sustained responders. The plot shows that the most prominent difference in cell composition between sustained and non-sustained responders is naive and stem cell memory T cells. Generalized linear model coefficients are shown on the X-axis and p-values ​​on the Y-axis. Figure 11B shows a box plot of the percentage of CD4 TSCM (upper panel) and CD8 TSCM (lower panel) in anti-BCMA CAR T cell medicines comparing sustained and non-sustained responders. TSCM cells were enriched in medicines in patients with sustained responses. [Figure 12] Figure 12A shows box plots of the percentage of LEF-1 expression determined by CyTOF in CD4 (top left panel) and CD8 (top center panel) T cells in anti-BCMA CAR T cell therapies comparing sustained and non-sustained responders. The percentage of LEF-1 expressing cells, as well as the gene expression of LEF-1, is increased in sustained responders compared to non-sustained responders, indicating enrichment of early memory T cells in these therapies. Figure 12A shows the correlation of patient sBCMA levels after 2 months of treatment with anti-BCMA CAR T cells with LEF-1 gene expression in the therapies. These data show an association between the early memory phenotype of the therapies and the depth of therapeutic response. [Figure 13]Figure 13 shows the percentage of live CD3+ cells expressing CCR7 (top left panel), LEF1 (top middle panel), and CD57 (top right panel) as determined by CyTOF in PBMCs and in anti-BCMA CAR T cells (DP). Figure 13 further shows the percentage of live CD3+ cells expressing CCR7 (Figure 13, bottom left panel), LEF-1 (Figure 13, bottom middle panel), and CD57 (Figure 13, bottom right panel) on the y-axis against the maximum vector copy number (VCN) determined by PCR on CD3+ cells extracted from whole blood at various time points after infusion of anti-BCMA CAR T cells on the x-axis. [Figure 14] Figure 14 shows the percentage of live CD3+ cells expressing CD57 (a marker of senescence), LEF-1, CCR7, and CD27 (memory cells) as a clustered heat map. Data were grouped using average linkage hierarchical clustering, and the top three clusters, as determined by a cluster dendrogram, were associated with patient clinical response at 6 months. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0117] Brief description of sequence identifiers SEQ ID NO:1 sets forth the amino acid sequence of the anti-BCMA CAR.

[0118] SEQ ID NO:2 sets forth the polynucleotide sequence encoding the anti-BCMA CAR.

[0119] In the above sequences, X, if present, refers to any amino acid or to the absence of an amino acid.

[0120] Detailed Description A. Overview The present invention generally relates to an improved method for producing T cell compositions. Although T cell therapy is more common than it was five years ago, the obstacles these therapies face are still, among others, poor efficacy or suboptimal performance. A solution is provided by the manufacturing method of the present invention, which significantly increases the performance of cell therapy products, such as CAR T cell products. Without intending to be bound by any particular theory, the inventors have unexpectedly discovered that shortening the T cell manufacturing period using PI3K inhibitors allows for further improvements in reducing cell dose and increasing cell performance and persistence compared to longer manufacturing processes using PI3K inhibitors. Surprisingly, the improved pharmaceutical products produced using the shorter PI3K inhibitor-based process show improved CD27 + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + CD4 + In certain embodiments, the improved pharmaceutical products produced using the shorter PI3K inhibitor-based process have an enriched population of central memory T cells (TCM). + , LEF1 + , and / or TCF1 + The resulting cells are capable of subsequently differentiating and providing sustained immune effector cell function.

[0121] Drug phenotyping and gene expression analysis also allow clinicians to determine how likely a particular drug is to work. The enriched T cells also contained increased gene expression of one or more of nuclear receptor subfamily 4 group A member 2 (NR4A2), CD229 (LY9), Lin-7 homolog A (LIN7A), wingless type MMTV integration site family, member 5B (WNT5B), B-cell CLL / lymphoma 6 (BCL6), early growth response 1 (EGR1), early growth response 2 (EGR2), activating transcription factor 3 (ATF3), and CC motif chemokine 1 (CCL1), interleukin 1A (IL-1A), and CC motif chemokine 5 (CCL5), as well as NAD(P)H quinone dehydrogenase 1 (NQO1), CyclinA1 (CCNA1), interleukin 17F (IL17F), epithelial membrane protein 1 (EMP1), Small Nuclear RNA Host Gene 19 (SNHG19), proline-rich 22 (PRR 22), including a reduction in the expression of one or more of the genes immunoglobulin-like domain-containing receptor 2 (ILDR2), ATPase family, AAA domain containing 3 (ATAD3), naked cuticle homolog 2 (NKD2), and WD repeat domain 62 (WDR62).

[0122] In certain embodiments, enriched T cells comprise increased gene expression of one or more of CCL1, NR4A2, ATF3, CCL5, and WNT5B, and decreased gene expression of one or more of NQO1 and NKD2.

[0123] In various embodiments, methods of producing T cells that have increased capacity for adoptive cell therapy are provided. In particularly preferred embodiments, engineered CAR T cell compositions are produced in the presence of a phosphatidyl-inositol-3 kinase (PI3K) inhibitor (e.g., ZSTK474 (CAS NO. 475110-96-4) for a period of time under conditions sufficient to increase the capacity of the engineered cells. In preferred embodiments, T cells are activated and stimulated in the presence of the PI3K inhibitor (for about 24 hours, 18-24 hours), transduced with a lentivirus comprising a polynucleotide encoding a CAR in the presence of the PI3K inhibitor (for about 24 hours, 18-24 hours), and expanded in the presence of the PI3K inhibitor for about 4 days or about 6 days (e.g., 6 days or a total of 8 days) after transduction.

[0124] In various embodiments, the 5-day T cell manufacturing process involves activating and stimulating the T cells in the presence of a PI3K inhibitor (about 24 hours, 18-24 hours), transducing the cells with a lentivirus containing a polynucleotide encoding a CAR in the presence of a PI3K inhibitor (about 24 hours, 18-24 hours), and expanding the cells in the presence of a PI3K inhibitor for about 4 days (e.g., 6 days total).

[0125] In various embodiments, the 7-day T cell manufacturing process involves activating and stimulating the T cells in the presence of a PI3K inhibitor (about 24 hours, 18-24 hours), transducing the cells with a lentivirus containing a polynucleotide encoding a CAR in the presence of a PI3K inhibitor (about 24 hours, 18-24 hours), and expanding the cells in the presence of a PI3K inhibitor for about 6 days (e.g., 8 days total).

[0126] In certain embodiments, methods of increasing expression of T cell activation or potency genes and / or decreasing expression of T cell differentiation or exhaustion genes are contemplated. The T cell compositions produced as contemplated herein are useful for treating, preventing, or ameliorating at least one symptom of cancer, e.g., a hematological malignancy.

[0127] In various embodiments, CD27 produced in the presence of a PI3K inhibitor + Current Good Manufacturing Practice (cGMP) manufactured compositions of enriched anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are contemplated. In certain embodiments, a shorter 5 or 7 day manufacturing process is used to detect and detect CD27 + , LEF1 + , CCR7 + and / or TCF1 + Generate an enriched population of anti-BCMA CAR T cells.

[0128] In various embodiments, CD27 + Enriched CD8 + TSCM-like T cells and CD27 + Enriched CD4 + Anti-BCMA CAR T cell compositions of TCM-like T cells are contemplated.

[0129] In various embodiments, LEF1 produced in the presence of a PI3K inhibitor + and / or CCR7 + and / or TCF1 + Current Good Manufacturing Practice (cGMP) manufactured compositions of enriched anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells are contemplated. In certain embodiments, the enriched population also comprises CD27 + These are anti-BCMA CAR T cells.

[0130] In various embodiments, CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Enriched CD8 + TSCM-like T cells and CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + Enriched CD4 + Anti-BCMA CAR T cell compositions of TCM-like T cells are contemplated.

[0131] Thus, the methods and compositions contemplated herein represent a quantitative improvement over existing adoptive cellular therapies.

[0132] Recombinant (i.e., engineered) DNA, peptide and oligonucleotide synthesis, immunoassays, tissue culture, transformation (e.g., electroporation, lipofection), enzymatic reactions, purification and related techniques and procedures may be generally performed as described in various general and more specific references in microbiology, molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology, which are cited and discussed throughout this specification. For example, Sambrook et al., Molecular Cloning: A Laboratory Manual, 3d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (John Wiley and Sons, updated July 2008); Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Glover, DNA Cloning: A Practical Approach, vol. I & II (IRL Press, Oxford Univ. Press USA, 1985); Current Protocols in Immunology (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M.Shevach、Warren Strober 2001 John Wiley & Sons、NY、NY);Real-Time PCR:Current Technology and Applications、Edited by Julie Logan、Kirstin Edwards and Nick Saunders、2009、Caister Academic Press、Norfolk、UK;Anand、Techniques for the Analysis of Complex Genomes、(Academic Press、New York、1992);Guthrie and Fink、Guide to Yeast Genetics and Molecular Biology(Academic Press、New York、1991);Oligonucleotide Synthesis(N.Gait、Ed.、1984);Nucleic Acid The Hybridization(B.Hames & S.Higgins、Eds.、1985);Transcription and Translation(B.Hames & S.Higgins、Eds.、1984);Animal Cell Culture(R.Freshney、Ed.、1986);Perbal、A Practical Guide to Molecular Cloning(1984);Next-Generation Genome Sequencing(Janitz、2008 Wiley-VCH);PCR Protocols(Methods in Molecular Biology)(Park、Ed.、3rd Edition、2010 Humana Press);Immobilized Cells And Enzymes(IRL Press、1986);the treatise、Methods In Enzymology(Academic Press、Inc.、N.Y.);Gene Transfer Vectors For Mammalian Cells(J.H.Miller and M.P.Calos eds., 1987, Cold Spring Harbor Laboratory); Harlow and Lane, Antibodies, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1998); Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986); Roitt, Essential Immunology, 6th Edition, (Blackwell Scientific Publications, Oxford, 1988); Current Protocols in Immunology (Q. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); Annual Review of Immunology; as well as research articles in journals such as, for example, Advances in Immunology.

[0133] B. Definition Before describing the present disclosure in more detail, it may be helpful to an understanding thereof to provide definitions of certain terms to be used herein.

[0134] Unless otherwise specified, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Although similar or equivalent methods and materials to those described herein can be used to carry out or test specific embodiments, preferred compositions, methods and materials embodiments are disclosed herein.For the purposes of this disclosure, the following terms are defined below.

[0135] The articles "a," "an," and "the" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, "an element" means one element or one or more elements.

[0136] As used herein, the term "about" or "approximately" refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that varies by up to 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1% from a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In certain embodiments, the term "about" or "approximately" when preceding a numerical value refers to a value that varies by a range of 15%, 10%, 5%, or 1%.

[0137] As used herein, the term "substantially" refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight, or length. In one embodiment, "substantially the same" refers to an amount, level, value, number, frequency, percentage, dimension, size, amount, weight, or length that produces about the same effect, e.g., a physiological effect, as the reference amount, level, value, number, frequency, percentage, dimension, size, amount, weight, or length.

[0138] Throughout this specification, unless the context requires otherwise, the words "comprise", "comprises" and "comprising" will be understood to imply the inclusion of the specified step or component or group of steps or components, but not the exclusion of any other step or component or group of steps or components. "Consisting of" means including and limited to everything that follows the word "consisting of". Thus, the phrase "consisting of" indicates that the recited elements are necessary or mandatory, and no other elements may be present. "Consisting essentially of" means including any elements that are limited to any elements recited thereafter, and other elements that do not interfere with or contribute to the activity or action specified in this disclosure for the recited elements. Thus, the phrase "consisting essentially of" indicates that the recited elements are necessary or mandatory, but that other elements are optional and may or may not be present depending on whether they materially affect the activity or action of the recited elements.

[0139] References throughout this specification to "one embodiment," "an embodiment," "a particular embodiment," "a related embodiment," "an embodiment," "an additional embodiment," or "a further embodiment," or combinations thereof, mean that the particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, the appearances of such phrases in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0140] As used herein, the term "T cell manufacturing" or "T cell manufacturing method" or equivalent terms refer to a process of making a therapeutic composition of T cells, which manufacturing method may include one or more or all of the steps of harvesting, stimulating, activating, transducing, and expanding. In a preferred embodiment, the expansion is for 5-7 days or less after transduction. A 5-day T cell manufacturing process includes activation and stimulation on day 0, transduction on day 1, and expansion until the end of day 5. A 7-day T cell manufacturing process includes activation and stimulation on day 0, transduction on day 1, and expansion until the end of day 7. A 10-day T cell manufacturing process includes activation and stimulation on day 0, transduction on day 1, and expansion until the end of day 10. In a preferred embodiment, the T cell manufacturing method includes the use of PI3K throughout the manufacturing process.

[0141] As used herein, the term "PI3K inhibitor" refers to a small organic molecule that binds to and inhibits at least one activity of PI3K. PI3K proteins can be divided into three classes: class 1 PI3K, class 2 PI3K, and class 3 PI3K. Class 1 PI3K exists as a heterodimer consisting of one of four p110 catalytic subunits (p110α, p110β, p110δ, and p110γ) and one of two regulatory subunit families. In certain embodiments, the PI3K inhibitor exhibits selectivity for one or more isoforms of the class 1 PI3K inhibitor (i.e., selectivity for one or more of p110α, p110β, p110δ, and p110γ or p110α, p110β, p110δ, and p110γ). In certain embodiments, the PI3K inhibitor does not exhibit isoform selectivity and is considered a "pan-PI3K inhibitor."

[0142] The term "T cell" or "T lymphocyte" is art-recognized and is intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. A T cell may be a T helper (Th) cell, such as a T helper 1 (Th1) cell or a T helper 2 (Th2) cell. A T cell may be a helper T cell (HT1; CD4 + T cells)CD4 + T cells, cytotoxic T cells (CTL; ​​CD8 + T cells), tumor-infiltrating cytotoxic T cells (TIL; CD8 + T cells), CD4 + CD8 + T cells, CD4 - CD8 - The T cells produced may be T cells, or any other subset of T cells. Preferably, the T cells produced are CD27 + T cells, CD27 + CD4 + T cells, and / or CD27 + CD8 + In a particular preferred embodiment, the produced T cells are enriched for LEF1 + and / or CCR7 + and / or TCF1 + T cells and / or LEF1 + and / or CCR7 + and / or TCF1 + CD4 + T cells and / or LEF1 + and / or CCR7 + and / or TCF1 + CD8 + In a particular preferred embodiment, the produced T cells are enriched for CD27 + LEF1 + and / or CCR7 + and / or TCF1 + T cells and / or CD27 + LEF1 + and / or CCR7 + and / or TCF1 + CD4 +T cells and / or CD27 + LEF1 + and / or CCR7 + and / or TCF1 + CD8 + Enriched for T cells. More preferably, the produced T cells are enriched for stem cell memory T cells (TSCM) and central memory T cells (TCM).

[0143] "Potent T cells" and "young T cells" are used interchangeably in certain embodiments and refer to a T cell phenotype in which the T cells have the capacity for proliferation and at the same time, are reduced in differentiation. In certain embodiments, young T cells have the phenotype of naive T cell TSCM or TCM. In various embodiments, the manufacturing methods contemplated herein produce more potent T cells, e.g., naive T cells, TSCM, or TCM. In certain embodiments, young T cells are enriched for one or more or all of the following biological markers: CD62L, CCR7, CD28, CD27, CD122, CD127, CD197, CD95, CD45RO, and CD38.

[0144] As used herein, the term "proliferation" refers to an increase in cell division, either symmetric or asymmetric division of cells. In certain embodiments, "proliferation" refers to symmetric or asymmetric division of T cells. "Increased proliferation" occurs when the number of cells in a treated sample increases compared to cells in an untreated sample.

[0145] As used herein, the term "differentiation" refers to a method of reducing the potency or proliferation of a cell or moving the cell to a more developmentally restricted state. In certain embodiments, differentiated T cells acquire immune effector cell functions.

[0146] An "immune effector cell" is any cell of the immune system that has one or more effector functions (e.g., cytotoxic cell-killing activity, cytokine secretion, induction of ADCC and / or CDC, etc.). Exemplary immune effector cells contemplated herein are T lymphocytes, particularly cytotoxic T cells (CTL; ​​CD8 + T cells), TILs, and helper T cells (HTLs; CD4 + T cells).

[0147] "Modified T cells" refers to T cells that have been modified by the introduction of a polynucleotide encoding a CAR as contemplated herein. Modified T cells include both genetically modified and non-genetically modified (e.g., episomal or extrachromosomal).

[0148] As used herein, the terms "genetically engineered" or "genetically modified" refer to the addition of additional genetic material in the form of DNA or RNA to the total genetic material in a cell.

[0149] The terms "genetically modified cells," "modified cells," and "redirected cells" are used interchangeably.

[0150] As used herein, the term "gene therapy" refers to the introduction of extra genetic material into a cell to restore, correct, or modify expression of a gene or to express a therapeutic polypeptide, e.g., a TCR or CAR and / or one or more cytokines, into the total genetic material. In certain embodiments, a T cell is modified to express a CAR without modifying the genome of the cell, e.g., by introducing into the cell an episomal vector that expresses the TCR or CAR in the cell.

[0151] The term "in vitro" generally refers to activities that occur at a location outside of an organism, such as experiments or measurements performed in an artificial environment outside of the organism, preferably with minimal changes to natural conditions, or experiments or measurements on living tissue. In certain embodiments, "in vitro" procedures include living cells or tissues taken from an organism and cultured or conditioned in a laboratory setup, usually under sterile conditions, typically for a few hours or up to about 24 hours, but up to 48 or 72 hours depending on the circumstances. In certain embodiments, such tissues or cells can be collected, frozen, and then thawed for in vitro processing. Tissue culture experiments or procedures that use living cells or tissues and last for several days or more are typically considered to be "in vitro", although in certain embodiments, the term can be used interchangeably with in vitro.

[0152] The term "in vivo" generally refers to activities that occur inside an organism, such as self-renewal and proliferation of cells. In one embodiment, the term "in vivo proliferation" refers to the ability of a population of cells to increase in number in vivo.

[0153] The term "stimulation" refers to a primary response induced by binding of a stimulatory molecule (e.g., the TCR / CD3 complex) with its cognate ligand, thereby mediating a signaling event, including, but not limited to, signaling through the TCR / CD3 complex.

[0154] "Stimulatory molecule" refers to a molecule on a T cell that specifically binds to a cognate stimulatory ligand.

[0155] As used herein, a "stimulatory ligand," when present on an antigen-presenting cell (e.g., aAPC, dendritic cell, B cell, etc.), can specifically bind to a cognate binding partner (herein referred to as a "stimulatory molecule") on a T cell, thereby mediating a primary response by the T cell, including but not limited to activation, initiation of an immune response, proliferation, etc. Stimulatory ligands include, but are not limited to, CD3 ligands, e.g., anti-CD3 antibodies, and CD2 ligands, e.g., anti-CD2 antibodies, and peptides, e.g., CMV, HPV, EBV peptides.

[0156] The term "activated" refers to a state of T cells that have been sufficiently stimulated to induce detectable cell proliferation. In certain embodiments, activation may also be associated with induced cytokine production and detectable effector functions. The term "activated T cells" refers, inter alia, to T cells that are proliferating. It is known that signals generated through the TCR alone are insufficient for full activation of T cells, and that one or more secondary or costimulatory signals are also required. Thus, T cell activation includes a primary stimulatory signal by the TCR / CD3 complex and one or more secondary costimulatory signals. Costimulation may be evidenced by proliferation and / or cytokine production by T cells that have received a primary activation signal, such as stimulation through the CDCD3 / TCR complex or CD2.

[0157] A "costimulatory signal" refers to a signal that, in combination with a primary signal, such as TCR / CD3 ligation, results in T cell proliferation, cytokine production, and / or upregulation or downregulation of specific molecules (e.g., CD28).

[0158] "Costimulatory ligand" refers to a molecule that binds to a costimulatory molecule. The costimulatory ligand may be soluble or may be provided on a surface. "Costimulatory molecule" refers to the cognate binding partner on a T cell that specifically binds to a costimulatory ligand (e.g., an anti-CD28 antibody).

[0159] As used herein, "autologous" refers to cells derived from the same subject. As used herein, "allogeneic" refers to cells of the same species that are genetically different from the compared cells. As used herein, "syngeneic" refers to cells of a different subject that are genetically identical to the compared cells. As used herein, "xenogeneic" refers to cells of a different species from the compared cells. In a preferred embodiment, the cells produced by the methods contemplated herein are autologous.

[0160] As used herein, the terms "individual" and "subject" are often used interchangeably and refer to any animal that exhibits symptoms of cancer that can be treated with the gene therapy vectors, cell-based therapeutic agents, and methods disclosed elsewhere herein. Suitable subjects (e.g., patients) include laboratory animals (e.g., mice, rats, rabbits, or guinea pigs), farm animals, domestic animals, or pets (e.g., cats or dogs). Non-human primates, preferably human patients, are also included. Exemplary subjects include human patients diagnosed with, at risk of, or having cancer or cancer.

[0161] As used herein, the term "patient" refers to a subject diagnosed with a particular indication that can be treated using the gene therapy vectors, cell-based therapeutic agents, and methods disclosed elsewhere herein.

[0162] As used herein, "treatment" or "treating" includes any beneficial or desired effect on the symptoms or pathology of a disease or pathological condition, and may include even a minimal reduction in one or more measurable markers of the disease or condition being treated, such as cancer. Treatment may optionally include either a reduction or alleviation of the symptoms of the disease or condition, or a delay in the progression of the disease or condition. "Treatment" does not necessarily indicate a complete elimination or cure of the disease or condition, or its associated symptoms.

[0163] As used herein, "prevent" and similar terms, such as "prevented" and "preventing", refer to an approach that aims to prevent, inhibit, or reduce the likelihood of occurrence or recurrence of a disease or condition, such as cancer. It also refers to delaying the onset or recurrence of a disease or condition, or delaying the onset or recurrence of symptoms of a disease or condition. As used herein, "prevention" and similar terms also include reducing the intensity, effect, symptoms, and / or burden of a disease or condition before the onset or recurrence of the disease or condition.

[0164] As used herein, the term "cancer" generally relates to certain diseases or conditions in which abnormal cells divide uncontrollably and can invade nearby tissues.

[0165] As used herein, the term "malignant" refers to a cancer in which tumor cells exhibit one or more of the following: uncontrolled proliferation (i.e., dividing beyond normal limits), invasion (i.e., invading and destroying adjacent tissues), and metastasis (i.e., spreading to other parts of the body via lymph or blood). As used herein, the term "metastasizing" refers to the spread of cancer from one part of the body to another. A tumor formed by the spread cells is called a "metastatic tumor" or "metastatic cancer." A metastatic tumor contains cells similar to those of the original tumor (primary tumor).

[0166] As used herein, the terms "benign" or "non-malignant" refer to tumors that may grow large but do not spread to other parts of the body. Benign tumors are self-limited and often do not invade or metastasize.

[0167] "Cancer cell" or "tumor cell" refers to an individual cell of a cancerous growth or cancerous tissue. "Tumor" generally refers to an expansion or lesion formed by the abnormal proliferation of cells, which may be benign, precancerous, or malignant. Most cancers form tumors, but some do not. For cancers that form tumors, the terms cancer (cell) and tumor (cell) are used interchangeably. The amount of tumor in an individual is the "tumor burden," and can be measured as the number, volume, or weight of tumors.

[0168] "Enhance" or "promote" or "increase" or "expand" generally refers to the ability of the compositions contemplated herein to produce, induce or generate a greater physiological response (i.e., downstream effect) compared to the response caused by vehicle or control molecule / composition. Measurable physiological responses include, among others, increased T cell expansion, activation, persistence, and / or cancer cell killing capacity, as will be apparent from the art and understanding of the present description. The amount of "increase" or "enhancement" is typically a "statistically significant" amount and may include an increase of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more (e.g., 500-fold, 1000-fold) (including all integers and decimals between and above 1, e.g., 1.5, 1.6, 1.7, 1.8, etc.) over the response caused by vehicle or control composition.

[0169] "Reduce" or "lower" or "lower" or "reduce" or "attenuate" generally refers to the ability of the compositions contemplated herein to produce, induce or cause a physiological response (i.e., downstream effect) that is smaller than the response caused by a vehicle or control molecule / composition. The amount of "reduction" or "reduced" is typically a "statistically significant" amount and can include a reduction that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 times or more (e.g., 500, 1000 times) (all integers and decimals in between, 1 or more, e.g., 1.5, 1.6, 1.7, 1.8, etc.) of the response caused by a vehicle or control composition (reference response).

[0170] "Maintain" or "preserve" or "maintain" or "no change" or "no substantial change" or "no substantial decrease" generally refers to the ability of the compositions contemplated herein to effect, elicit, or produce a similar physiological response in a cell (i.e., a downstream effect) compared to the response produced by either a vehicle or a control molecule / composition. A comparable response is one that is not substantially different or not measurably different from the reference response.

[0171] "Antigen (Ag)" refers to a compound, composition, or substance that can stimulate antibody production or a T-cell response in an animal, including compositions (such as compositions that include tumor-specific proteins) that are injected into or absorbed into an animal. Antigens react with the products of specific humoral or cellular immunity, including those induced by heterologous antigens, such as the antigens disclosed herein. A "target antigen" or "target antigen or subject" is an antigen to which the binding domain of a CAR contemplated herein is designed to bind.

[0172] "Epitope" or "antigenic determinant" refers to a region of an antigen to which a binding agent binds.

[0173] "Polypeptide," "polypeptide fragment," "peptide," and "protein" are used interchangeably in their conventional sense, i.e., amino acid sequence, unless specified to the contrary. A polypeptide is not limited to a particular length, e.g., a polypeptide may contain a full-length protein sequence or a fragment of a full-length protein, and a polypeptide may include post-translational modifications of the polypeptide, such as, for example, glycosylation, acetylation, phosphorylation, and other natural and non-natural modifications known in the art. A polypeptide may be prepared using any of a variety of known recombinant and / or synthetic techniques. Polypeptides contemplated herein specifically encompass a CAR of the present disclosure, or a sequence having one or more amino acid deletions, additions, and / or substitutions of a CAR disclosed herein. In certain embodiments, the term "polypeptide" further includes variants, fragments, and fusion polypeptides.

[0174] As used herein, "isolated peptide" or "isolated polypeptide" refers to the in vitro isolation and / or purification of a peptide or polypeptide molecule from the cellular environment and from association with other components of a cell. That is, it is not substantially associated with in vivo substances. Similarly, "isolated cell" refers to a cell obtained from an in vivo tissue or organ and substantially free of extracellular matrix.

[0175] A polypeptide variant may differ from a naturally occurring polypeptide by one or more substitutions, deletions, additions, and / or insertions. Such variants may be naturally occurring or may be synthetically generated, for example, by modifying one or more of the above-mentioned polypeptide sequences. For example, in certain embodiments, it may be desirable to improve the binding affinity and / or other biological properties of a CAR by introducing one or more substitutions, deletions, additions, and / or insertions into the binding domain, hinge, TM domain, costimulatory signaling domain, or primary signaling domain of a CAR polypeptide. The polypeptides of the invention preferably include polypeptides having at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% amino acid identity thereto.

[0176] Polypeptides include "polypeptide fragments." Polypeptide fragments refer to fragments of biologically active polypeptides, which may be monomeric or polymeric, and have amino-terminal deletions, carboxyl-terminal deletions, and / or internal deletions or substitutions in naturally occurring or recombinantly produced polypeptides. In certain embodiments, a polypeptide fragment may contain an amino acid chain at least 5 to about 500 amino acids in length. In certain embodiments, fragments are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 150, 200, 250, 300, 350, 400, or 450 or more amino acids in length.

[0177] Fusion polypeptides and fusion proteins refer to polypeptides having at least 2, 3, 4, 5, 6, 7, 8, 9, 10 or more polypeptide segments.

[0178] As used herein, the term "polynucleotide" or "nucleic acid" refers to messenger RNA (mRNA), RNA, genomic RNA (gRNA), positive strand RNA (RNA(+)), negative strand RNA (RNA(-)), genomic DNA (gDNA), complementary DNA (cDNA), or recombinant DNA. Polynucleotides include single-stranded and double-stranded polynucleotides. Preferably, the polynucleotides of the invention include polynucleotides or variants having at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to any of the reference sequences described herein (see, e.g., Sequence Listing), typically wherein the variant maintains at least one biological activity of the reference sequence. In various exemplary embodiments, the invention contemplates polynucleotides, including, in part, expression vectors, viral vectors, and transfecting plasmids, as well as compositions and cells containing them.

[0179] As used herein, an "isolated polynucleotide" refers to a polynucleotide that has been purified from sequences that naturally flank it, e.g., a DNA fragment that has been removed from sequences that normally flank the fragment. An "isolated polynucleotide" also refers to a complementary DNA (cDNA), recombinant DNA, or other polynucleotide that is not found in nature and that has been produced by the hand of man.

[0180] "Control elements," "control sequences," present in an expression vector are non-translated regions of the vector, including origins of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine Dalgarno or Kozak sequences), introns, polyadenylation sequences, 5' and 3' non-translated regions, which interact with host cellular proteins to effect transcription and translation. Such factors may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation factors may be used, including ubiquitous and inducible promoters.

[0181] An "endogenous" regulatory sequence is one that is naturally linked to a given gene in the genome. An "exogenous" regulatory sequence is one that is placed in juxtaposition to a gene by means of genetic engineering (i.e., molecular biological techniques) such that transcription of that gene is directed by the linked enhancer / promoter. A "heterologous" regulatory sequence is an exogenous sequence that originates from a species different from the cell being genetically engineered.

[0182] As used herein, the term "promoter" refers to a recognition site in a polynucleotide (DNA or RNA) to which an RNA polymerase binds. The RNA polymerase initiates transcription of a polynucleotide operably linked to the promoter. In certain embodiments, promoters that operate in mammalian cells contain an AT-rich region located approximately 25-30 bases upstream from the site where transcription is initiated, and / or a separate sequence, a CNCAAT region, located 70-80 bases upstream from the transcription start site, where N can be any nucleotide.

[0183] The term "enhancer" refers to a DNA segment that contains a sequence that can provide enhanced transcription, and in some cases can function regardless of orientation relative to another control sequence. Enhancers can function in concert with or additively with promoter elements and / or other enhancer elements. The term "promoter / enhancer" refers to a DNA segment that contains a sequence that can provide both promoter and enhancer functions.

[0184] The term "operably linked" refers to a juxtaposition where the described components are in a relationship permitting them to function in their intended manner. In one embodiment, the term refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter and / or enhancer) and a second polynucleotide sequence, e.g., a polynucleotide of interest, where the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

[0185] The term "vector" is used herein to refer to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule.

[0186] Additional definitions are set forth throughout this disclosure.

[0187] CT cell production method The T cells produced by the methods contemplated herein provide an improved adoptive immunotherapy composition. The present invention contemplates a 5-7 day T cell manufacturing process using a PI3K inhibitor that generates more potent T cells compared to the existing 10 day T cell manufacturing process using a PI3K inhibitor. Without intending to be bound by any particular theory, it is believed that the T cell compositions, e.g., anti-BCMA CAR T cells, produced by the methods contemplated herein include an increased number of more potent (enriched) T cell populations. In certain embodiments, the 5-7 day manufacturing process contemplated herein produces T cells that are more potent than CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + In certain embodiments, the 5-7 day method of production contemplated herein results in an enriched population of CD27 T cells. + and LEF1 + and / or CCR7 + and / or TCF1 + In certain embodiments, the 5-7 day method of production contemplated herein results in an enriched population of CD27 T cells. + and LEF1 + and CCR7 + and / or TCF1 + In certain embodiments, the 5-7 day method of production contemplated herein results in an enriched population of CD27 T cells. + and LEF1 + and CCR7 + and TCF1 +In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of CD27 T cells. + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + CD4 + In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of central memory T cells (TCM). + CD8 + Stem cell memory T cells (TSCM) and LEF1 + CD4 + In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of central memory T cells (TCM). + LEF1 + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + LEF1 + CD4 + In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of central memory T cells (TCM). + LEF1 + CCR7 + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + LEF1 + CCR7 + CD4 + In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of central memory T cells (TCM). + LEF1 + TCF1 + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + LEF1 + TCF1 + CD4 + In certain embodiments, the 5-7 day production method contemplated herein results in an enriched population of central memory T cells (TCM). + LEF1 + CCR7+ TCF1 + CD8 + Stem Cell Memory T Cells (TSCM) and CD27 + LEF1 + CCR7 + TCF1 + CD4 + Results in enriched populations of central memory T cells (TCM). Furthermore, a 5-7 day T cell manufacturing process using a PI3K inhibitor contains differential gene expression signatures compared to T cells manufactured in a 10 day process using a PI3K inhibitor. Adoptive cell therapies, e.g., CAR T cell therapies, containing these enriched cell populations allow clinicians to reduce cell doses and increase cell potency and persistence without compromising therapeutic efficacy.

[0188] In various embodiments, the method of producing T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a viral vector comprising a polynucleotide encoding a CAR, and culturing and expanding the transduced T cells for about 4 to about 6 days, all method steps being performed in the presence of a PI3K inhibitor.

[0189] Examples of PI3K inhibitors suitable for use in certain embodiments of the T cell manufacturing methods contemplated herein include, but are not limited to, BKM120 (Class 1 PI3K inhibitor, Novartis), XL147 (Class 1 PI3K inhibitor, Exelixis), (Pan-PI3K inhibitor, GlaxoSmithKline), and PX-866 (Class 1 PI3K inhibitor, p110α, p110β, and p110γ isoforms, Oncotherion). Other illustrative examples of selective PI3K inhibitors include, but are not limited to, BYL719, GSK2636771, TGX-221, AS25242, CAL-101, ZSTK474, and IPI-145. Further illustrative examples of pan-PI3K inhibitors include, but are not limited to, BEZ235, LY294002, GSK1059615, TG100713, and GDC-0941.

[0190] In the most preferred embodiment contemplated herein, the manufacturing method employs the PI3K inhibitor ZSTK474 (CAS NO. 475110-96-4).

[0191] In various embodiments, the PI3K inhibitor is used throughout the manufacturing process at a concentration of at least 1 nM, at least 2 nM, at least 5 nM, at least 10 nM, at least 50 nM, at least 100 nM, at least 200 nM, at least 500 nM, at least 1 μM, at least 10 μM, at least 50 μM, at least 100 μM, or at least 1 M.

[0192] In a preferred embodiment, the PI3K inhibitor is used at a concentration of about 1 μM throughout the manufacturing process.

[0193] T cells can be obtained from a number of sources, including, but not limited to, peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue at the site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be obtained from a unit of blood drawn from a subject using any number of techniques known to those of skill in the art, such as sedimentation, e.g., FICOLL™ separation.

[0194] In certain embodiments, PBMCs are used as a source of T cells in the T cell manufacturing methods contemplated herein. + , CD8 + , or CD4 + and CD8 + The T lymphocytes form a heterogeneous population of T lymphocytes that may include other mononuclear cells such as monocytes, B cells, NK cells, and NKT cells.

[0195] In a preferred embodiment, the T cell manufacturing process begins with obtaining a source of PBMCs by apheresis from an individual's circulating blood. The apheresis product typically contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, the cells collected by apheresis may be washed to remove the plasma fraction and place the cells in a suitable buffer or medium for further processing. The cells may be washed with PBS or another suitable solution lacking calcium, magnesium, and most if not all other divalent cations. As will be appreciated by those skilled in the art, the washing step may be accomplished by methods well known to those skilled in the art, such as using a semi-automated flow-through centrifuge. Examples include a Cobe 2991 cell processor, a Baxter CytoMate, or similar. After washing, the cells may be resuspended in various biocompatible buffers or other saline solutions, with or without buffer. In certain embodiments, undesirable components of the apheresis sample may be removed in the resuspension medium directly in the cells. Methods of T cell manufacturing are disclosed in U.S. Patent Application No. 15 / 306,729, entitled "Improved Methods for Manufacturing Adoptive Cell Therapies," filed October 25, 2016, U.S. Patent Application No. 15 / 316,792, entitled "Improved T Cell Compositions," filed December 6, 2016, and U.S. Patent Application No. 16 / 060,184, entitled "Improved T Cell Compositions," filed June 7, 2018, which are incorporated herein by reference in their entireties. In certain embodiments, populations of cells comprising T cells, e.g., PBMCs, are used in the manufacturing methods contemplated herein. In other embodiments, isolated or purified T cell populations are used in the manufacturing methods contemplated herein.

[0196] PBMCs may be treated to activate and stimulate the T cell population contained therein to achieve a sufficient therapeutic dose of the T cell composition. In certain embodiments, T cells may be generally activated and expanded using methods described, for example, in U.S. Patent Nos. 6,352,694, 6,534,055, 6,905,680, 6,692,964, 5,858,358, 6,887,466, 6,905,681, 7,144,575, 7,067,318, 7,172,869, 7,232,566, 7,175,843, 5,883,223, 6,905,874, 6,797,514, and 6,867,041. These patents are incorporated herein by reference in their entireties.

[0197] In a preferred embodiment, T cells are activated and stimulated in the presence of a PI3K inhibitor, such as ZSTK474. The method contemplated herein differs from existing methods in that only a single round of activation and stimulation is performed, whereas methods in the art typically use two, three, four, or five or more rounds of activation and expansion.

[0198] T cell activation can be achieved by providing a primary costimulatory signal through the T cell TCR / CD3 complex or by stimulating the CD2 surface protein. The TCR / CD3 complex may be stimulated by contacting the T cell with a suitable CD3 binding agent, such as a CD3 ligand or an anti-CD3 monoclonal antibody. Exemplary CD3 antibodies include, but are not limited to, OKT3, G19-4, BC3 and 64.1. In addition to the primary stimulatory signal provided through the TCR / CD3 complex or through CD2, induction of a T cell response requires a secondary costimulatory signal. In certain embodiments, a CD28 binding agent may be used to provide the costimulatory signal. Exemplary CD28 binding agents include, but are not limited to, natural CD28 ligands, e.g., the natural ligands for CD28 (e.g., members of the B7 family of proteins, e.g., B7-1 (CD80) and B7-2 (CD86); and anti-CD28 monoclonal antibodies, or fragments thereof capable of cross-linking the CD28 molecule, such as monoclonal antibodies 9.3, B-T3, XR-CD28, KOLT-2, 15E8, 248.23.2, and EX5.3D10.

[0199] In a preferred embodiment, T cells are activated with soluble anti-CD3 antibody and stimulated to proliferate with anti-CD28 antibody. In a specific embodiment, the anti-CD3 antibody and the anti-CD8 antibody are immobilized, tethered, or bound to beads, e.g., paramagnetic beads such as Dynabeads.

[0200] In certain embodiments, the anti-CD3 and anti-CD8 antibodies are localized on the surface of the cell. In a preferred embodiment, the primary and costimulatory ligands, such as anti-CD3 and anti-CD28 antibodies, are presented on antigen-presenting cells (e.g., aAPCs, dendritic cells, B cells, etc.) present in the PBMC fraction.

[0201] In certain embodiments, the T cells are activated and stimulated for about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, or about 30 hours. In certain embodiments, the T cells are activated and stimulated for about 24 hours.

[0202] In certain embodiments, the T cells are activated and stimulated for about 16 hours to about 30 hours, about 16 hours to about 24 hours, about 18 hours to about 24 hours, or about 20 hours to about 24 hours.

[0203] In a preferred embodiment, the cells subjected to the activation and stimulation steps are transduced in the presence of a PI3K inhibitor, e.g., ZSTK474. The purpose of this step of the process is to transduce immune effector cells, although other cells may be present and transduced, e.g., CD4 + , CD8 + , or CD4 + and CD8 + The T cells are transduced as well as other mononuclear cells such as monocytes, B cells, NK cells, and NKT cells. In a preferred embodiment, the activated and stimulated T cells are transduced with a viral vector comprising a polynucleotide encoding a CAR. Examples of viral vector systems suitable for use in certain contemplated embodiments include, but are not limited to, adeno-associated virus (AAV), retroviral vectors, e.g., lentiviral vectors, herpes simplex virus vectors, adenoviral vectors, and vaccinia virus vectors.

[0204] In a preferred embodiment, cells are transduced with a lentivirus comprising a polynucleotide encoding a CAR. As used herein, the term "lentivirus" refers to a group (or genus) of complex retroviruses. Examples of lentiviruses include, but are not limited to, HIV (including human immunodeficiency virus, HIV type 1 and HIV type 2), Visna-Maedi virus (VMV), Caprine arthritis-encephalitis virus (CAEV), Equine infectious anemia virus (EIAV), Feline immunodeficiency virus (FIV), Bovine immunodeficiency virus (BIV), and Simian immunodeficiency virus (SIV). In one embodiment, HIV-1-based vector backbone (i.e., HIV cis-acting sequence elements) is preferred.

[0205] In various embodiments, lentiviral vectors contemplated herein include a chimeric 5' long terminal repeat (LTR), e.g., a chimeric CMV / 5'LTR promoter, and one or more or all of the following accessory elements: cPPT / FLAP (Zennou et al., 2000, Cell, 101:173), a Psi (Ψ) packaging signal (Clever et al., 1995. J. of Virology, Vol. 69, No. 4; pp. 2101-2109), an extrusion element, e.g., an RRE (Cullen et al., 1991. J. Virol. 65:1053; and Cullen et al., 1991. Cell, 10:1054). 58:423), a poly(A) sequence, optionally a WPRE (Zufferey et al., 1999, J. Virol., 73:2886) or HPRE (Huang et al., Mol. Cell. Biol., 5:3864), an insulator element, a selectable marker, or a cell suicide gene, and a modified self-inactivating (SIN) 3' LTR. A "self-inactivating" (SIN) vector refers to a replication-deficient vector, e.g., a retroviral or lentiviral vector, in which the right (3') LTR enhancer-promoter region, known as the U3 region, has been modified (e.g., by deletion or substitution) to prevent viral transcription beyond the first round of viral replication. In certain embodiments, the lentiviral vector is pseudotyped with the vesicular stomatitis virus G-protein (VSV-G) envelope protein, allowing the vector to infect a broad range of cells. In certain embodiments, the lentiviral vector is produced by known methods. See, e.g., Kutner et al., BMC Biotechnol. 2009;9:10. doi:10.1186 / 1472-6750-9-10; Kutner et al. Nat. Protoc. 2009;4(4):495-505. doi:10.1038 / nprot.2009.22.

[0206] In certain embodiments, after activation and stimulation, the cells are transduced for about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, or about 30 hours. In certain embodiments, the cells are transduced for about 24 hours.

[0207] In certain embodiments, after activation and stimulation, the cells are transduced for about 16 hours to about 30 hours, about 16 hours to about 24 hours, about 18 hours to about 24 hours, or about 20 hours to about 24 hours.

[0208] In a preferred embodiment, after transduction, the cells are cultured under conditions that promote the proliferation of immune effector cells, e.g., T cells, CAR T cells, or anti-BCMA CAR T cells, in the presence of a PI3K inhibitor, e.g., ZSTK474. Unexpectedly, the inventors found that after an extremely short proliferation or expansion period of 1, 2, 3, 4, 5, or 6 days (after transduction), CD27 + We have discovered that highly potent cell therapy products enriched with cells, TCMs, and TSCMs can be produced.

[0209] In certain embodiments, conditions or growth media suitable for T cell culture include an appropriate medium (e.g., Minimal Essential Media or RPMI Media 1640 or X-vivo 15 (Lonza)) and one or more factors necessary for growth and activity, including but not limited to serum (e.g., fetal bovine serum or human serum), interleukin-2 (IL-2), insulin, IFN-γ, IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL-15, TGFβ, and TNF-α, or any other additives suitable for cell growth known to one of skill in the art. Further exemplary cell culture media include, but are not limited to, RPMI 1640, Clicks, AIM-V, DMEM, MEM, a-MEM, F-12, X-Vivo 1 5, and X-Vivo 20, Optimizer, which are supplemented with amino acids, sodium pyruvate, and vitamins, and are serum-free or supplemented with an appropriate amount of serum (or plasma) or a combination of hormones and / or cytokines in sufficient amounts for T cell proliferation and expansion. Examples of other additives for T cell proliferation include, but are not limited to, detergents, plasma protein fractions, pH buffers such as HEPES, and reducing agents such as N-acetyl-cysteine ​​and 2-mercaptoethanol.

[0210] In a preferred embodiment, T cells are cultured for expansion for 1, 2, 3, 4, 5, or 6 days in T cell growth medium (TCGM) and prepared with X-VIVO 15 supplemented with 10 mM HEPES, 2 mM GlutaMax, and 5% human AB serum. In a preferred embodiment, the manufacturing process is carried out in the presence of one or more cytokines, preferably IL-2, IL-7, and / or IL-15, more preferably IL-2.

[0211] In certain embodiments, the cell growth or proliferation phase is carried out for about 1 to about 6 days, about 2 to about 6 days, about 3 to about 6 days, or about 4 to about 6 days. In preferred embodiments, the cell growth or proliferation phase is carried out for about 4 to about 6 days.

[0212] In certain embodiments, the cell growth or proliferation phase is carried out for about 1 day, about 2 days, about 3 days, about 4 days, about 5 days, or about 6 days. In a preferred embodiment, the cell growth or proliferation phase is carried out for about 4 days. In a particularly preferred embodiment, the cell growth or proliferation phase is carried out for about 6 days.

[0213] In various embodiments, the T cell composition is produced in the presence of one or more inhibitors of the PI3K pathway. The inhibitor may target one or more activities or a single activity within the pathway. Without intending to be bound by any particular theory, treating or contacting T cells with one or more inhibitors of the PI3K pathway during the stimulation, activation, and / or expansion phases of the production process will preferentially increase young T cells, thereby producing a superior therapeutic T cell composition.

[0214] In various embodiments, a method of manufacturing CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding a CAR, and culturing and expanding the transduced T cells for about 4 to about 6 days, all method steps being performed in the presence of a PI3K inhibitor, and the expanded CAR T cells are enriched for TCM and TSCM cells compared to a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days.

[0215] In certain embodiments, the method of manufacturing anti-BCMA CAR T cells includes expanding or expanding culture for about 4 to about 6 days, which results in a greater number of CD4 T cells with a TCM phenotype compared to a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + About 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold enrichment of T cells and CD8 + The T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold.

[0216] In various embodiments, a method of manufacturing CAR T cells includes activating a T cell population, stimulating and expanding the T cell population, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding a CAR, e.g., an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2), culturing and expanding the transduced T cells for about 4 to about 6 days, all method steps being performed in the presence of a PI3K inhibitor, and the expanded CAR T cells have a higher CD27 expression level than a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + The cells are enriched.

[0217] In certain embodiments, the method of manufacturing anti-BCMA CAR T cells comprising expansion or expansion culture for about 4 to about 6 days reduces the CD27 + T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold.

[0218] In certain embodiments, a method of manufacturing anti-BCMA CAR T cells comprising an expansion or expansion culture for about 4 to about 6 days enriches or increases the number of one or more CD27, CD25, CD127, TCF1, LEF1, CD28, and / or CCR7 expressing T cells by about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold as compared to a manufacturing process in which the transduced cells are cultured with a PI3K inhibitor for about 9 days. In certain embodiments, a method of manufacturing anti-BCMA CAR T cells comprising an expansion or expansion culture for about 4 to about 6 days enriches or increases the number of one or more CD27, CD25, CD127, TCF1, and / or LEF1, and / or CCR7 expressing T cells by about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold compared to a manufacturing process in which the transduced cells are cultured with a PI3K inhibitor for about 9 days. In certain embodiments, a method of manufacturing anti-BCMA CAR T cells comprising an expansion or expansion culture for about 4 to about 6 days results in about a 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold reduction in the number of T cells expressing one or more of granzyme A, granzyme B, perforin, T-bet, and EOMES compared to a manufacturing process in which the transduced cells are cultured with a PI3K inhibitor for about 9 days.

[0219] In various embodiments, a method of manufacturing anti-BCMA CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR comprising an amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2), culturing and expanding the transduced T cells for about 4 to about 6 days, all method steps being performed in the presence of a PI3K inhibitor, and the expanded T cells have a higher CD27 expression level than a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + CD4 + TCM and CD27 + CD8 + TSCM cells are enriched.

[0220] In certain embodiments, the method of manufacturing anti-BCMA CAR T cells includes growing or expanding culture for about 4 to about 6 days, which results in a greater number of CD27 T cells with a TCM phenotype compared to a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + CD4 + T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold and have a CD27 + CD8 + The T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold.

[0221] In various embodiments, a method of manufacturing anti-BCMA CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR comprising an amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2), culturing and expanding the transduced T cells for about 4 to about 6 days, all method steps being performed in the presence of a PI3K inhibitor, and the expanded T cells show increased CD27 expression compared to a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + and / or LEF1 + and / or CCR7 + and / or TCF1 + CD4 + TCM and CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + CD8 + TSCM cells are enriched.

[0222] In certain embodiments, the method of manufacturing anti-BCMA CAR T cells includes growing or expanding culture for about 4 to about 6 days, which results in a greater number of CD27 T cells with a TCM phenotype compared to a manufacturing process in which the transduced cells are cultured in a PI3K inhibitor for about 9 days. + and / or LEF1+ and / or CCR7 + and / or TCF1 + CD4 + T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold and have a CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + CD8 + The T cells are enriched about 1.5-fold, about 2.0-fold, about 2.5-fold, about 3-fold, about 3.5-fold, about 4-fold, about 4.5-fold, or about 5-fold.

[0223] In various embodiments, a method of producing anti-BCMA CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO: 1 (e.g., SEQ ID NO: 2), culturing the transduced T cells to expand for about 4 to about 6 days, all of the steps of the method being performed in the presence of a PI3K inhibitor, and wherein the gene expression signature of the proliferating T cells is nuclear receptor subfamily 4 group A member 2 (NR4A2), CD229 (LY9), Lin-7 homolog A (LIN7A), wingless-type MMTV integration site family, member 5B (WNT5B), B enriched or increased expression of one or more or all of BCL6, early growth response 1 (EGR1), early growth response 2 (EGR2), activating transcription factor 3 (ATF3), CC motif chemokine 1 (CCL1), interleukin 1A (IL-1A), and CC motif chemokine 5 (CCL5), and NAD(P)H quinone dehydrogenase 1 (NQO1), cyclin A1 (CCNA1), interleukin 17F (IL17F), epithelial membrane protein 1 (EMP1), Small Intestine Lymphoma 2 (SIRP2), and IL-1A. It reduced the expression of one or more or all of the following genes: Nucleolar RNA Host Gene 19 (SNHG19), Proline-rich 22 (PRR22), Immunoglobulin-like domain-containing receptor 2 (ILDR2), ATPase family, AAA domain containing 3 (ATAD3), Naked cuticle homolog 2 (NKD2) and WD repeat domain 62 (WDR62).

[0224] In various embodiments, a method of producing anti-BCMA CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2), and culturing and expanding the transduced T cells for about 4 to about 6 days, all of the method steps being performed in the presence of a PI3K inhibitor, and wherein the gene expression signature of the expanded T cells has enriched or increased expression of CCL1, NR4A2, ATF3, CCL5, and WNT5B, and decreased expression of NKD2 and NQO1.

[0225] "Gene expression" refers to the relative expression levels and / or expression patterns of genes in biological samples, T cell populations, e.g., anti-BCMA CAR T cells, produced in the presence or absence of a PI3K inhibitor, or produced for different lengths of time in the presence of a PI3K inhibitor. Gene expression may be measured at the level of cDNA, RNA, mRNA, or combinations thereof. Methods for measuring gene expression include, but are not limited to, quantitative real-time, PCR, high-density oligonucleotide arrays, nanostring transcriptome profiling, or RNA sequencing (RNA-Seq).

[0226] In certain embodiments, T cells, including CAR T cells, e.g., anti-BCMA CAR T cells, produced using a 7 day manufacturing process with a PI3K inhibitor as contemplated herein are characterized by at least a 1.5-fold or at least a 2-fold increase in expression of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, relative to T cells produced using a 10 day manufacturing process as contemplated herein. T cells produced using the 7 day process with a PI3K inhibitor are further characterized by a unique gene expression signature, where expression of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11 signature genes selected from the group consisting of: NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 is increased by at least 1.5 fold or at least 2 fold compared to T cells produced using a 10 day process with a PI3K inhibitor.

[0227] In certain embodiments, T cells, including CAR T cells, e.g., anti-BCMA CAR T cells, produced using a 7 day manufacturing process with a PI3K inhibitor as contemplated herein are characterized by at least a 1.5-fold or at least a 2-fold decrease in expression of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1, relative to T cells produced using a 10 day manufacturing process as contemplated herein. T cells produced using the 7 day process with a PI3K inhibitor are further characterized by a unique gene expression signature, where expression of one, two, three, four, five, six, seven, eight, nine, or all ten of the signature genes selected from the group consisting of: NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62 is reduced by at least 1.5 fold or at least 2 fold compared to T cells produced using a 10 day process with a PI3K inhibitor.

[0228] In certain embodiments, T cells, including CAR T cells, e.g., anti-BCMA CAR T cells, manufactured using a 7 day manufacturing process with a PI3K inhibitor as contemplated herein are characterized by at least a 1.5 fold or at least a 2 fold increase in expression of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, and at least a 1.5 fold or at least a 2 fold decrease in expression of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1, relative to T cells manufactured using a 10 day manufacturing process as contemplated herein. The T cells produced using the 7 day process with a PI3K inhibitor are further characterized by a unique gene expression signature, where expression of one, two, three, four, five, six, seven, eight, nine, ten or all eleven signature genes selected from the group consisting of: NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 is increased by at least 1.5 fold or at least 2 fold, and expression of one, two, three, four, five, six, seven, eight, nine or all ten signature genes selected from the group consisting of: NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62 is decreased by at least 1.5 fold or at least 2 fold compared to T cells produced using a 10 day process with a PI3K inhibitor.

[0229] In various embodiments, a method of producing an anti-BCMA CAR T cell includes activating a T cell population, stimulating the T cell population to expand, and producing an anti-BCMA CAR T cell comprising the amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2). transducing T cells with a lentiviral vector comprising a polynucleotide encoding a CAR; culturing and expanding the transduced T cells for about 4 to about 6 days, all steps of the method being performed in the presence of a PI3K inhibitor, the expanded T cells being enriched for TCM and TSCM cells, and wherein gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold greater in the cultured T cells expanded in culture for about 4 to about 6 days compared to T cells expanded in culture for about 9 days.

[0230] In various embodiments, a method of producing anti-BCMA CAR T cells includes activating a T cell population, stimulating the T cell population to expand, transducing the T cells with a lentiviral vector comprising a polynucleotide encoding an anti-BCMA CAR comprising an amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2), culturing and expanding the transduced T cells for about 4 to about 6 days, all steps of the method being performed in the presence of a PI3K inhibitor, the expanded T cells are enriched for TCM, TSCM cells, and gene expression of one, two, three, four, five, six, seven, eight, nine or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5 fold less in the cultured T cells expanded in culture for about 4 to about 6 days compared to T cells expanded in culture for about 9 days.

[0231] In various embodiments, the method of producing an anti-BCMA CAR T cell includes activating a T cell population, stimulating the T cell population to expand, and producing an anti-BCMA CAR T cell comprising the amino acid sequence set forth in SEQ ID NO:1 (e.g., SEQ ID NO:2). transducing T cells with a lentiviral vector comprising a polynucleotide encoding a CAR; culturing and expanding the transduced T cells for about 4 to about 6 days, all steps of the method being performed in the presence of a PI3K inhibitor, the expanded T cells being enriched for TCM and TSCM cells, and having at least 1.5-fold greater gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B; and (iii) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 gene expression is at least 1.5-fold less in cultured T cells expanded in culture for about 4 to about 6 days compared to T cells expanded in culture for about 9 days.

[0232] The manufacturing methods contemplated herein may further include cryopreservation of PBMCs and / or cryopreservation of the manufactured T cell composition prior to the start of the manufacturing process. Cryopreservation of adoptive cell therapy allows for the storage, testing, transport, and release of the therapeutic agent for use in human subjects. T cells are cryopreserved such that upon thawing, the cells remain viable. If desired, the cryopreserved cells can be thawed, expanded, and expanded for more such cells. As used herein, "cryopreservation" refers to preserving cells by cooling to a temperature below zero, such as (typically) 77K or -196°C (the boiling point of liquid nitrogen). Cryopreservatives are often used at temperatures below zero so that the cells being stored are not damaged by freezing at low temperatures or heating to room temperature. Cryopreservatives and optimal cooling rates can protect against cell damage. Cryoprotectants that can be used include, but are not limited to, dimethylsulfoxide (DMSO) (Lovelock and Bishop, Nature, 1959;183:1394-1395; Ashwood-Smith, Nature, 1961;190:1204-1205), glycerol, polyvinylpyrrolidine (Rinfret, Ann. NY Acad. Sci., 1960;85:576), polyethylene glycol (Sloviter and Ravdin, Nature, 1962;196:48), as well as CryoStor CS10, CryoStor CS5, and CryoStor CS2. In a preferred embodiment, the produced T cells are formulated in a solution containing 50:50 PlasmaLyte A and CryoStor CS10. The preferred cooling rate is 1°-3°C / min. After at least 2 hours, the T cells will have reached a temperature of -80°C and can be placed directly into liquid nitrogen (-196°C) for permanent storage, such as in a long-term cryogenic storage vessel.

[0233] D. Chimeric Antigen Receptor The methods contemplated herein are used to produce more potent adoptive cell therapy that redirects the cytotoxicity of immune effector cells to cancer cells expressing a target antigen. In a preferred embodiment, the methods contemplated herein include transducing activated and stimulated T cells with a viral vector encoding a chimeric antigen receptor (CAR) to redirect immune effector cells.

[0234] CARs are molecules that combine antibody-based specificity for a target antigen (e.g., a tumor antigen) with a T cell receptor activating intracellular domain to generate a chimeric protein that exhibits specific anti-tumor cell immune activity. CARs contemplated herein include a signal peptide, an extracellular domain that binds to a specific target antigen (also referred to as a binding domain, or an antigen-specific binding domain), a transmembrane domain, and an extracellular domain that binds to one or more intracellular signaling domains.

[0235] In certain embodiments, the CAR comprises an extracellular binding domain that specifically binds to a target polypeptide. In certain embodiments, the extracellular binding domain comprises an antibody or an antigen-binding fragment thereof. In one preferred embodiment, the binding domain comprises an scFv. In another preferred embodiment, the binding domain comprises one or more camelid VHH antibodies or single domain antibodies.

[0236] In certain embodiments, the CAR is the alpha folate receptor (FRα), α v β 6Integrin, B-cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lecithin-like molecule-1 (CLL-1), CD 2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T-cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), epithelial cell adhesion molecule (EPCAM), ephrin type A receptor 2 (EPHA2), fibroblast activation protein (F AP), Fc receptor-like 5 (FCRL5), fetal acetylcholinesterase receptor (AchR), ganglioside G2 (GD2), ganglioside G3 (GD3), glypican-3 (GPC3), EGFR family including ErbB2 (HER2), IL-10Rα, IL-13Rα2, kappa, cancer / testis antigen 2 (LAGE-1A), lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), melanoma antigen genes (MAGE)-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, melanoma antigen recognized by T cells 1 (MelanA or MART1), mesothelin (MSLN), MUC1, MUC16, MHC class I chain-related protein A (MICA), MHC class I chain-related protein B (MICB), neural cell adhesion molecule (NCAM), cancer / testis antigen 1 (NY-ESO-1), polysialic acid;the extracellular domain comprises an antigen that binds to an antigen selected from the group consisting of placenta specific 1 (PLAC1), antigen preferentially expressed in melanoma (PRAME), prostate stem cell antigen (PSCA), prostate specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X-breakpoint 2 (SSX2), survivin, tumor associated glycoprotein 72 (TAG72), tumor endothelial marker 1 (TEM1 / CD248), tumor endothelial marker 7-related (TEM7R), trophoblast glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, vascular endothelial growth factor receptor 2 (VEGFR2), and Wilms' tumor 1 (WT-1);

[0237] In a preferred embodiment, the CAR comprises an extracellular domain that binds to a B cell maturation antigen.

[0238] In certain embodiments, CAR comprises a hinge domain.Exemplary hinge domains include, but are not limited to, hinge regions derived from the extracellular domains of type 1 membrane proteins, such as CD8α and CD4, and may be the wild-type hinge regions of these molecules or may be modified.In preferred embodiments, CAR comprises a CD8α hinge region.

[0239] The transmembrane (TM) domain of the CAR connects the extracellular binding moiety and the intracellular signaling domain, anchoring the CAR to the cell membrane of the immune effector cell. The TM domain may be derived from either natural, synthetic, semi-synthetic, or recombinant sources. Exemplary TM domains may be derived from (i.e., include) at least the transmembrane region(s) of the alpha, beta, gamma, or delta chain of the T cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD71, CD80, CD86, CD134, CD137, CD152, CD154, AMN, and PDCD1.

[0240] In a preferred embodiment, the CAR contains a TM domain derived from CD8α. In another embodiment, the CAR contemplated herein contains a TM domain derived from CD8α and a short oligo- or polypeptide linker, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids in length, which links the TM domain of the CAR to the intracellular signaling domain. A glycine-serine linker provides a particularly suitable linker.

[0241] In a preferred embodiment, the CAR comprises an intracellular signaling domain comprising one or more costimulatory signaling domains and a primary signaling domain.

[0242] Primary stimulatory signaling domains may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs, or ITAMs.

[0243] Exemplary ITAM-containing primary signaling domains suitable for use in CARs contemplated in certain embodiments include those derived from FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d. In particularly preferred embodiments, the CAR comprises a CD3ζ primary signaling domain and one or more costimulatory signaling domains. The intracellular primary signaling domain and the costimulatory signaling domain can be linked in tandem in any order to the carboxyl terminus of the transmembrane domain.

[0244] In certain embodiments, the CAR comprises one or more costimulatory signaling domains to enhance the efficacy and expansion of T cells expressing the CAR receptor.

[0245] Illustrative examples of such costimulatory molecules suitable for use in the CARs contemplated in certain embodiments include, but are not limited to, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, CARD11, CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DAP10, LAT, SLP76, TRAT1, TNFR2, and ZAP70. In one embodiment, the CAR comprises one or more costimulatory signaling domains selected from the group consisting of CD28, CD137, and CD134, and a CD3zeta major signaling domain.

[0246] In a preferred embodiment, the CAR comprises a CD8α signal peptide, an extracellular domain that binds BCMA, a CD8α hinge and transmembrane domain, a CD137 costimulatory domain, and a CD137, and a CD3ζ primary signaling domain. In a more preferred embodiment, the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1, and in an even more preferred embodiment, the anti-BCMA CAR comprises the polynucleotide sequence set forth in SEQ ID NO:2.

[0247] E. Compositions and Formulations The compositions contemplated herein comprise a therapeutically effective amount of CAR T cells. In a preferred embodiment, the compositions contemplated herein comprise a therapeutically effective amount of anti-BCMA CAR T cells. Compositions include, but are not limited to, pharmaceutical compositions. A "pharmaceutical composition" refers to a composition formulated in a pharma- ceutical or physiologically acceptable solution for administration to a cell or an animal, alone or in combination with one or more other therapeutic modalities. It is also understood that, if desired, the composition may be administered in combination with other agents as well, such as, for example, cytokines, growth factors, hormones, small molecules, chemotherapeutic agents, prodrugs, drugs, antibodies, or a variety of other pharma- ceutical active agents. There is virtually no limit to the other components that may be included in the composition, provided that the added agents do not adversely affect the ability of the composition to deliver the intended therapy.

[0248] In a preferred embodiment, the compositions contemplated herein comprise a cGMP manufactured population of CAR T cells enriched for T cells that express one or more of CD27, LEF1, and TCF1 on the cell surface. In a preferred embodiment, the enriched population of CAR T cells manufactured using a 5-7 day process in the presence of a PI3K inhibitor has at least 10% CD27 + , at least 15% CD27 + , at least 20% CD27 + , at least 25% CD27 + , at least 30% CD27 + , at least 35% CD27 + , at least 40% CD27 + , at least 45% CD27 + , or at least 50% CD27 + In certain embodiments, the enriched population of CAR T cells produced using a 5-7 day process in the presence of a PI3K inhibitor contains at least 10% CD27 + Includes LEF1 + , and / or TCF1 + , at least 15% CD27 + , LEF1 +, and / or TCF1 + , at least 20% CD27 + , LEF1 + , and / or TCF1 + , at least 25% CD27 + , LEF1 + , and / or TCF1 + , at least 30% CD27 + , LEF1 + , and / or TCF1 + , at least 35% CD27 + , LEF1 + , and / or TCF1 + , at least 40% CD27 + , LEF1 + , and / or TCF1 + , at least 45% CD27 + , LEF1 + , and / or TCF1 + , or at least 50% CD27 + , LEF1 + , and / or TCF1 + In certain embodiments, the enriched population of CAR T cells produced using a 5-7 day process in the presence of a PI3K inhibitor contains at least 10% CD27 + LEF1 + TCF1 + , at least 15% CD27 + LEF1 + TCF1 + , at least 20% CD27 + LEF1 + TCF1 + , at least 25% CD27 + LEF1 + TCF1 + , at least 30% CD27 + LEF1 + TCF1 + , at least 35% CD27 + LEF1 + TCF1 + , at least 40% CD27 + LEF1 + TCF1+ , at least 45% CD27 + LEF1 + TCF1 + , or at least 50% CD27 + LEF1 + TCF1 + In certain embodiments, the T cells are CCR7 + It is also.

[0249] As used herein, the phrase "pharmacologically acceptable" is employed to refer to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0250] As used herein, a "pharmaceutical acceptable carrier" includes, but is not limited to, an adjuvant, carrier, excipient, lubricant, sweetener, diluent, preservative, dye / colorant, flavoring agent, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, surface active agent, or emulsifier approved by the U.S. Food and Drug Administration as acceptable for use in humans or veterinary medicine. Exemplary pharma- ceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch, cellulose and derivatives, e.g., cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; tragacanth; malt; gelatin; talc; cocoa butter, waxes, animal and vegetable fats, paraffin, silicones, bentonite, silicic acid, zinc oxide, oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil, glycols such as propylene glycol, polyols such as glycerin, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate, agar; buffers such as magnesium hydroxide and aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer's solution, ethyl alcohol; phosphate buffers, and other compatible substances employed in pharmaceutical formulations.

[0251] In certain embodiments, the composition comprises an amount, more preferably a therapeutically effective amount, of a CAR-expressing T cell as contemplated herein.

[0252] As used herein, the term "amount" or "dosage" refers to an "effective amount," "effective dose," "effective amount," or "effective dose" of CAR T cells sufficient to achieve a beneficial or desired prophylactic or therapeutic result, including a clinical result.

[0253] A "therapeutically effective amount" or "therapeutically effective dose" of a CAR T cell is also an amount in which the therapeutically beneficial effects outweigh any toxic or deleterious effects of the CAR T cell, e.g., CRS. The term "therapeutically effective amount" includes an amount effective to "treat" a subject (e.g., a patient). In one embodiment, a therapeutically effective dose is the minimally effective dose (MED) of a CAR T cell to treat multiple myeloma in a subject. In one embodiment, a therapeutically effective dose is the maximum tolerated dose (MTD) of an anti-BCMA CAR T cell that does not result in unresolvable CRS in the subject. In a preferred embodiment, a therapeutically effective amount of CAR T cells, e.g., anti-BCMA CAR T cells manufactured using a 5-day or 7-day manufacturing process in the presence of a PI3K inhibitor, is administered to a subject, where the amount of cells is less than the amount of cells required to achieve a comparable result from a CAR T cell manufactured using a 10-day manufacturing process using a PI3K inhibitor.

[0254] In certain embodiments, the compositions are preferably formulated for parenteral administration, for example, intravascular (intravenous or intraarterial) administration. In a preferred embodiment, the compositions contemplated herein are intravenously injected into a subject in a single dose.

[0255] In one embodiment, the CAR in the composition administered to the subject + The amount of T cells is at least about 5.0 x 10 7 Cells, at least about 15.0 x 10 7 Cells, at least about 45.0 x 10 7 Cells, at least about 80.0 x 10 7 cells, or at least about 12.0 × 10 8 It is a cell.

[0256] In one embodiment, the CAR in the composition administered to the subject + The amount of T cells is approximately 5.0 × 10 7 Cell super, approx. 15.0×10 7 Cell super, approx. 45.0×10 7 Super cell, approximately 80.0×10 7 More than 12.0 x 10 cells, or approximately 8 It is beyond the cell.

[0257] In one embodiment, the CAR in the composition administered to the subject + The amount of T cells is approximately 5.0 × 10 7 Cells ~ approx. 15.0×10 7 cells, approximately 5.0 x 10 7 Cells ~ approx. 45.0×10 7 cells, approximately 5.0 x 10 7 Cells ~ approx. 80.0×10 7 cells, or approximately 5.0 x 10 7 Cells ~ approx. 12.0×10 8 It is a cell.

[0258] For the applications presented herein, the cells will generally be in sub-liter volumes, which may be up to 500 mL, or even up to 250 mL or 100 mL.

[0259] In certain embodiments, the pharmaceutical composition comprises a therapeutically effective amount of CAR T cells in combination with one or more pharma- ceutical or physiologically acceptable carriers, diluents, or excipients.

[0260] A pharmaceutical composition comprising a therapeutically effective dose of CAR T cells may include a buffer such as neutral buffered saline, phosphate buffered saline, a carbohydrate such as glucose, mannose, sucrose or dextran, an amino acid such as mannitol, a protein, a polypeptide or glycine, an antioxidant, a chelating agent such as EDTA or glutathione, an adjuvant (e.g., aluminum hydroxide), and a preservative.

[0261] Liquid pharmaceutical compositions, whether in solution, suspension or other similar form, may contain one or more of the following: sterile diluents such as water for injection, saline, preferably saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono- or diglycerides that may be provided as a solvent or suspending medium, polyethylene glycol, glycerin, propylene glycol or other solvents, antibacterial agents such as benzyl alcohol or methylparabens, antioxidants such as ascorbic acid or sodium sulfite, chelating agents such as ethylenediaminetetraacetic acid, buffers such as acetates, citrates or phosphates, and agents for adjusting tonicity such as sodium chloride or dextrose. Parenteral preparations may be enclosed in ampoules, disposable syringes, or multiple dose vials made of glass or plastic. Pharmaceutical compositions for injection are preferably sterile.

[0262] In certain embodiments, the CAR T cell compositions contemplated herein are formulated in a pharmaceutically acceptable cell culture medium. Such compositions are suitable for administration to human subjects. In certain embodiments, the pharmaceutically acceptable cell culture medium is a serum-free medium.

[0263] Serum-free media have several advantages over serum-containing media, including a simpler and more transparent composition, lower amounts of contaminants, elimination of potential sources of infectious entities, and lower costs. In various embodiments, serum-free media may be animal-free and optionally protein-free. Optionally, the media may contain biopharmaceutical acceptable recombinant proteins. "Animal-free" media refers to media whose components are derived from non-animal sources. Recombinant proteins replace natural animal proteins in animal-free media, whose nutrients are obtained from synthetic, plant, or microbial sources. "Protein-free" media, in contrast, are defined as being substantially protein-free.

[0264] Examples of serum-free media for use in certain compositions include, but are not limited to, QBSF-60 (Quality Biological, Inc.), StemPro-34 (Life Technologies), and X-VIVO 10.

[0265] In a preferred embodiment, the compositions comprising the CAR T cells contemplated herein are formulated in a solution comprising PlasmaLyte A.

[0266] In another preferred embodiment, the composition comprising CAR T cells contemplated herein is formulated in a solution comprising a cryopreservation medium.For example, a cryopreservation medium comprising a cryopreservative may be used to maintain high cell activity after thawing.Exemplary cryopreservation media used in certain compositions include, but are not limited to, CryoStor CS10, CryoStor CS5, and CryoStor CS2.

[0267] In a more preferred embodiment, the compositions comprising CAR T cells contemplated herein are formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.

[0268] F. Treatment method The modified T cells produced by the methods contemplated herein provide improved adoptive immunotherapy for use in the treatment of a variety of conditions, including, but not limited to, cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immune disorders. In certain embodiments, the specificity of primary T cells is redirected to tumor or cancer cells by genetically modifying the primary T cells with a CAR contemplated herein.

[0269] In certain embodiments, the CAR T cell compositions produced by the methods contemplated herein are used to treat solid tumors or cancers, including, but not limited to, liver cancer, pancreatic cancer, lung cancer, breast cancer, bladder cancer, brain cancer, bone cancer, thyroid cancer, kidney cancer or skin cancer.

[0270] In certain embodiments, the CAR T cell compositions manufactured using the methods contemplated herein are used to treat acute leukemia (e.g., ALL, AML, and myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia), chronic leukemia (e.g., CLL, SLL, CML, HCL), polycythemia vera, lymphoma, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, Waldenstrom's hypergammaglobulinemia, and heavy chain disease.

[0271] In certain embodiments, the CAR T cell compositions produced using the methods contemplated herein are used to treat B cell malignancies, including, but not limited to, multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), and chronic lymphocytic leukemia (CLL).

[0272] Multiple myeloma is a B-cell malignancy of mature plasma cell morphology characterized by neoplastic transformation of a single clone of these types of cells. These plasma cells proliferate in the BM and may invade adjacent bone and occasionally the blood. Variant forms of multiple myeloma include overt multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, nonsecretory myeloma, IgD myeloma, osteosclerotic myeloma, isolated plasmacytoma of bone, and extramedullary plasmacytoma (see, e.g., Braunwald et al. (eds), Harrison's Principles of Internal Medicine, 15th Edition (McGraw-Hill 2001)).

[0273] Non-Hodgkin's lymphoma encompasses a large group of cancers of lymphocytes (white blood cells). Non-Hodgkin's lymphoma can occur at any age and is often characterized by larger than normal lymph nodes, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. For example, non-Hodgkin's lymphoma can be divided into aggressive (fast growing) and indolent (slow growing) types. Non-Hodgkin's lymphoma can originate from B cells and T cells, but as used herein, the terms "non-Hodgkin's lymphoma" and "B cell non-Hodgkin's lymphoma" are used interchangeably. B-cell non-Hodgkin lymphomas (NHL) include Burkitt lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma (CLL / SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-cell lymphoma, and mantle cell lymphoma. Lymphomas that arise after bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas.

[0274] Chronic lymphocytic leukemia (CLL) is an indolent (slow-growing) cancer that causes a slow increase in immature white blood cells called B lymphocytes or B cells. The cancer cells spread through the blood and bone marrow and may also affect lymph nodes or other organs such as the liver and spleen. CLL eventually causes the bone marrow to fail. In the later stages of the disease, the disease may be called small lymphocytic lymphoma.

[0275] In certain embodiments, a composition comprising a therapeutically effective amount of anti-BCMA CAR T cells is administered to a subject to treat multiple myeloma or lymphoma.

[0276] In certain embodiments, a composition comprising a therapeutically effective amount of anti-BCMA CAR T cells is administered to a subject to treat relapsed / refractory multiple myeloma. "Relapse" refers to a diagnosis of cancer relapse or signs and symptoms of cancer relapse after a period of improvement or remission. "Refractory" refers to a cancer that is resistant or unresponsive to therapy with a particular therapeutic agent. A cancer may be refractory from the start of treatment (i.e., unresponsive to initial exposure to a therapeutic agent) or may become refractory as a result of developing resistance to a therapeutic agent either during the initial treatment period or during subsequent treatment periods.

[0277] In certain embodiments, the compositions contemplated herein are administered to a subject with relapsed / refractory multiple myeloma who has been unsuccessfully treated with one, two, three, or more treatments, including at least one proteasome inhibitor and / or an immunomodulatory drug (IMiD). In one embodiment, the subject's multiple myeloma is refractory to three treatment regimens, including at least one proteasome inhibitor and an IMiD. In one embodiment, the subject's multiple myeloma is double refractory to one or more treatment regimens.

[0278] Examples of proteasome inhibitors in which a subject's multiple myeloma is refractory include, but are not limited to, bortezomib and carfilzomib.

[0279] Examples of IMiDs in which the subject's multiple myeloma is refractory include, but are not limited to, thalidomide, lenalidomide, and pomalidomide.

[0280] Examples of other treatments in which multiple myeloma may be refractory include, but are not limited to, dexamethasone and antibody-based therapies selected from the group consisting of elotuzumab, daratumumab, MOR03087, isatuximab, bevacizumab, cetuximab, siltuximab, tocilizumab, ersilimomab, azintrel, rituximab, tosizumab, milatuzumab, lucatuzumab, dacetuzumab, figitumumab, dalotuzumab, AVE1642, tabalumab, pembrolizumab, pidilizumab, and nivolumab.

[0281] In one embodiment, the subject's multiple myeloma is refractory to treatment with daratumumab.

[0282] In certain embodiments, the subject's multiple myeloma is refractory to treatment with an IMiD, a proteasome inhibitor, and dexamethasone.

[0283] The methods contemplated herein may further comprise treating the relapsed / refractory multiple myeloma subject with autologous hematopoietic stem cell transplant prior to administration of the anti-BCMA CAR T cell composition.

[0284] The methods contemplated herein may further include lymphodepleting the subject prior to administration of an anti-BCMA CAR T cell composition contemplated herein, e.g., lymphodepleting chemotherapy is completed 1-4 days (e.g., 1, 2, 3, or 4 days) prior to administration. In certain embodiments, lymphodepletion includes administering one or more of melphalan, cytoxan, cyclophosphamide, and fludarabine. In one embodiment, the subject is lymphodepleted with cyclophosphamide 300 mg / m2 and fludarabine 30 mg / m2 prior to administration of an anti-BCMA CAR T cell composition contemplated herein.

[0285] All publications, patent applications, and issued patents cited in this specification are hereby incorporated by reference as if each individual publication, patent application, or issued patent was specifically and individually indicated to be incorporated by reference.

[0286] The above invention has been described in detail with reference to figures and examples for purposes of clarity and understanding, but in light of the teachings of the present invention, it will be readily apparent to those skilled in the art that certain changes and modifications may be made without departing from the spirit or scope of the appended claims. The following examples are provided for illustrative purposes only and not for limiting purposes. Those skilled in the art will readily recognize various non-critical parameters that can be changed or modified to produce essentially similar results. EXAMPLES

[0287] Example 1 Improving the manufacturing process Cells were harvested from multiple myeloma donors by leukapheresis and PBMCs were isolated using a density gradient on a Cell Saver Elite. PBMCs were washed and then resuspended in T cell growth medium (TCGM) with 250 IU / mL IL-2. Pre-wash and post-wash cell counts, viability, and PBMC FACS analysis were performed. Washed PBMCs were either cryopreserved until activation or used fresh. On day 0, T cells were activated and stimulated by culturing in TCGM with 250 IU / mL IL-2, 1 μm ZSTK474 (CAS NO. 475110-96-4), 50 ng / mL anti-CD3 antibody, and 50 ng / mL anti-CD28 antibody for cultures for approximately 18-24 hours. PBMC cultures were transduced with lentivirus encoding an anti-BCMA CAR (e.g., SEQ ID NO. 1, SEQ ID NO. 2) for approximately 18-24 hours. PBMC cultures were then cultured for 4, 6, or 9 days (5, 7, and 10 day manufacturing processes, respectively) in TCGM containing 250 IU / mL IL-2 and 1 μM ZSTK474 for T cell expansion. At each of one or more days of expansion, aliquots of cells were randomly taken and cells were counted, viability determined, cryopreserved, and characterized for PBMCs using FACS analysis. Expanded cells were harvested, washed, cryopreserved in a controlled rate freezer at a temperature of at least -80°C, and stored in the vapor phase of a liquid nitrogen storage tank.

[0288] Example 2 Improved manufacturing process modulates T cell phenotype Five multiple myeloma donor PBMC cell lots were used to manufacture anti-BMCA CAR T cells using the 7-day or 10-day manufacturing process described in Example 1, in the presence or absence of the PI3K inhibitor ZSTK474. At the end of the T cell expansion culture, cells were stained with anti-human antibodies against CD3, CD62L, CCR7, and CD45RA and analyzed by flow cytometry. Each dot plot is divided into 10 dots, with 10 dots, and 10 dots. +Gating on lymphocytes. Anti-BCMA CAR T cell drug (DP) produced in the presence of ZSTK474 for 7 days increased marker expression for a more potent T cell phenotype compared to anti-BCMA CAR T cell DP produced in the presence of ZSTK474 for 10 days or in the absence of a PI3K inhibitor. Figure 1.

[0289] Example 3 Improved manufacturing process modulates T cell differentiation Five multiple myeloma donor PBMC cell lots were used to manufacture anti-BMCA CAR T cells in the presence of the PI3K inhibitor ZSTK474 using the 7-day or 10-day manufacturing process described in Example 1. At the end of the T cell expansion culture, cells were stained with metal-labeled anti-human antibodies against CCR7, CD25, CD28, CD122, ICOS, CD45RO, CD57, and TIM3 and analyzed by CyTOF. Each dot plot is divided into 10 dots, 10 dots, and 10 dots. + Gating on lymphocytes. Anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 7 days increased expression of markers for a less differentiated T cell phenotype and decreased expression of markers for a more differentiated T cell phenotype compared to anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 10 days (Figure 2).

[0290] Example 4 Improved manufacturing process CD27 + Enriching T cells Five multiple myeloma donor PBMC cell lots were used to manufacture anti-BMCA CAR T cells using the 7-day or 10-day manufacturing process described in Example 1, in the presence or absence of the PI3K inhibitor ZSTK474. At the end of the T cell expansion culture, cells were stained with metal-labeled anti-human antibodies against CD4, CD8, and CD27 and analyzed by CyTOF. The VISNE plot shows CD27 expression in the different cell populations. The gated populations were CD27 +Anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 7 days were significantly higher in CD27 T cells than anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 10 days or in the absence of a PI3K inhibitor. + , LEF1 + , and / or TCF1 + Figure 3. An unexpected and dramatic increase in enriched T cells.

[0291] Example 5 Enriched CD27 + The T cell population has a strong T cell phenotype Five multiple myeloma donor PBMC cell lots were used to manufacture anti-BMCA CAR T cells using the 7-day or 10-day manufacturing process described in Example 1 in the presence of the PI3K inhibitor ZSTK474. At the end of the T cell expansion culture, cells were stained with metal-labeled anti-human antibodies against CCR7, CD25, CD28, HLA-DR, and TIM3 (Figure 4A), as well as CD45RO, CD57, CD70, CD244, and PD-1 (Figure 4B), and analyzed by CyTOF. VISNE plots show marker expression in the different cell populations. Gated populations are CD27 + represents enriched T cells. Anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 7 days increased marker expression for a less differentiated T cell phenotype and decreased marker expression for a more differentiated T cell phenotype compared to anti-BCMA CAR T cell DPs produced in the presence of ZSTK474 for 10 days (Figures 4A-4B).

[0292] Example 6 Improved manufacturing process CD27 + Modulates T cell activation profile Five multiple myeloma donor PBMC cell lots were used to manufacture anti-BMCA CAR T cells in the presence of the PI3K inhibitor ZSTK474 using the 7-day or 10-day manufacturing process described in Example 1. At the end of the T cell expansion culture, cells were stained with metal-labeled anti-human antibodies against CD27, CD28, ICOS, HLA-DR, CD25, and TIM3 and analyzed by CyTOF. CD27 identified by VISNE + The T cell phenotype of the enriched cells was determined by CD4 + T cells (Figure 5, top) and CD8 + Marker expression in T cells (Figure 5, bottom) was analyzed. Anti-BCMA CAR T cell DP produced in the presence of ZSTK474 for 10 days has a decreased activation profile and increased exhaustion profile compared to anti-BCMA CAR T cell DP produced in the presence of ZSTK474 for 7 days.

[0293] Example 7 Improved manufacturing process modulates T cell gene expression Multiple myeloma PBMC lots were used to manufacture anti-BCMA CAR T cells as described in Example 1 for 7 days (n=1) or 10 days (n=13) in the absence of PI3K inhibitor ZSTK474, or for 7 days (n=10) or 10 days (n=6) in the presence of PI3K inhibitor. Approximately 100 ng of total RNA was extracted from anti-BCMA CAR T cell DP, mixed with Nanostring's Immunology V2 probe kit, and the transcriptional profile was analyzed. A heat map of the top 50 differentially expressed genes between manufacturing conditions is shown in Figure 6. Anti-BCMA CAR T cell DPs manufactured for 7 days generally show increased expression of T cell memory phenotype genes and genes related to T cell activation and proliferation, as well as decreased expression of genes related to cell death, compared to DPs manufactured for 10 days.

[0294] Example 8 Anti-BCMA CAR T cells in Daudi tumor mouse model A Daudi tumor mouse model was established to compare the efficacy of drugs manufactured using a 7-day process with that manufactured using a 10-day process. Healthy donor PBMCs were activated and stimulated, transduced with a lentiviral vector encoding an anti-BCMA CAR, and expanded for 7 or 10 days in the presence of IL-2 and a PI3K inhibitor (see Example 1). Ten days prior to adoptive cell therapy, NSG mice were injected with 2×10 6 Mice were intravenously injected with 2.5, 5, or 10 × 10 firefly luciferase-labeled Daudi tumor cells. 6 Anti-BCMA CAR + T cells transduced with BCMA or vehicle were injected into the tumor. Tumor burden was monitored by luminescence. Anti-BCMA CAR T cells produced in the 7-day process showed lower CAR T cell proliferation than cells produced in the 10-day process. + Figure 7. Better efficacy demonstrated by the increased ability to control tumor growth with increasing dose.

[0295] Example 9 Anti-BCMA CAR T cell phenotype PBMC cell lots from 15 multiple myeloma donors were used to manufacture anti-BMCA CAR T cells using the 7-day or 10-day manufacturing process described in Example 1 in the presence of the PI3K inhibitor ZSTK474. At the end of the T cell expansion culture, cells were stained with a panel of approximately 36 T cell phenotypic metal-labeled anti-human antibodies and analyzed by CyTOF. The phenotypic antibodies allow for discrimination between the following T cell phenotypes: naive T cells (Tnaive), central memory T cells (TCM), effector memory T cells (EM), effector T cells (TEff), and stem cell memory T cells (TSCM). The T stem cell memory subset is distinct from the naive T cell quadrant (CCR7 + CD45RO - ) by CD95 expression on T cell subsets. + Each DP lot analyzed is shown as a function of % of enriched cells. + CD4 +T cells positively correlated with a TCM-like phenotype, whereas CD27 + CD8 + T cells positively correlate with a TSCM-like phenotype. FIG.

[0296] Example 10 CD8 + Anti-BCMA CAR T cell phenotype CD8 generated in Example 9 + T cell data was analyzed using FlowSOM. FlowSOM identified 20 distinct T cell clusters. Three major groups of T cells were identified based on cluster 4 (enriched for memory T cell markers, e.g., CD27, CD25, CD127, TCF1, LEF1, CD28, CCR7) and cluster 5 (enriched for effector T cell markers, e.g., granzyme A, granzyme B, perforin, T-bet, EOMES). For subjects treated with anti-BCMA CAR T cells, %CD27 + CD8 + The anti-BCMA CAR T cell manufacturing methods and clinical responses were analyzed. The 7-day manufacturing process generally demonstrated increased expression of T cell memory markers and CD27 expression compared to the 10-day manufacturing process. + Resulting in anti-BCMA CAR T cells with an increased enriched cell population.

[0297] Example 11 Anti-BCMA CAR T cell gene expression analysis PBMC cell lots from 12 multiple myeloma donors were used to manufacture anti-BCMA CAR T cells using the 7-day (n=8) or 10-day (n=4) manufacturing process described in Example 1 in the presence of the PI3K inhibitor ZSTK474. Approximately 100ng of total RNA was extracted from anti-BCMA CAR T cell DP and mixed with Nanostring's Immunology V2 probe kit. Data was QCed with NSolver software (Nanostring) and differential gene expression analysis was performed. A heatmap of the top 25 differentially expressed genes (p-value 0.05) was generated between the 7-day and 10-day manufacturing processes. For subjects treated with anti-BCMA CAR T cells, %CD27 + The anti-BCMA CAR T cell manufacturing methods and clinical responses were analyzed. The 7-day manufacturing process generally demonstrated increased expression of T cell memory markers and CD27 expression compared to the 10-day manufacturing process. + Resulting in anti-BCMA CAR T cells with an increased enriched cell population.

[0298] Example 12 Anti-BCMA CAR T cell gene expression analysis Five multiple myeloma donor PBMC cell lots were each split into two groups, one group was used to manufacture anti-BMCA CAR T cells using a 7-day manufacturing process, and the other group was used to manufacture anti-BMCA CAR T cells using a 10-day manufacturing process. CAR T cells were manufactured in the presence of the PI3K inhibitor ZSTK4, as described in Example 1.

[0299] Approximately 100ng of total RNA was extracted from anti-BCMA CAR T-cell DPs and mixed with Nanostring's Immunology V2 probe kit. Data were QCed with NSolver software (Nanostring) and differential gene expression analysis was performed.

[0300] An aliquot of anti-BCMA CAR T cell DP total RNA was also used for RNA sequencing (RNA-Seq). Cells were thawed / washed / counted and tested for viability (requiring >70% viability). 2–3 × 10 6 Total RNA from cells was extracted using TRIAZOL. For total RNA, RNA was harvested using phenol / chloroform extraction and Qiagen miRNA-easy kit. RNA was isolated using polyA bead capture strategy. RNA quality / quantity was determined by Tapestation 2200 (RIN value >7 required). Sequencing libraries were prepared by Illumina TruSeq RNA. Library quality check was done by Tapestation 2200 (DNA kit) and sequenced using NextSeq550 instrument. Data was analyzed using QC / alignment method.

[0301] The top 11 upregulated genes and the top 9 downregulated genes by fold change (FC) relative to the manufacturing process on day 7 are shown in Table 1 . [Table 1]

[0302] Example 13 Anti-BCMA CAR T cell gene expression analysis Five multiple myeloma donor PBMC cell lots were each split into two groups, one group was used to manufacture anti-BMCA CAR T cells using a 7-day manufacturing process, and the other group was used to manufacture anti-BMCA CAR T cells using a 10-day manufacturing process. CAR T cells were manufactured in the presence of the PI3K inhibitor ZSTK4, as described in Example 1.

[0303] An aliquot of anti-BCMA CAR T cell DP total RNA was used to perform RNA sequencing (RNA-Seq). Cells were thawed / washed / counted and tested for viability (required >70% viability). 2–3 × 10 6Total RNA from cells was extracted using TRIAZOL. For total RNA, RNA was harvested using phenol / chloroform extraction and Qiagen miRNA-easy kit. RiboErase was used for rRNA depletion. RNA quality / quantity was determined by Tapestation 2200 (RIN value >7 required). RNA quality / quantity was determined by Tapestation 2200 (RIN value >7 required). Sequencing libraries were prepared by Illumina TruSeq RNA. Library quality check was done by Tapestation 2200 (DNA kit) and sequenced using NextSeq550 instrument. Data was analyzed using QC / alignment methods.

[0304] CCL1, NR4A2, ATF3, CCL5, and WNT5B were the top 25 upregulated genes, and NKD2 and NQO1 were the top 10 downregulated genes by fold change (FC) compared to the day 7 manufacturing process.

[0305] Example 14 Anti-BCMA CAR T cell therapy PBMCs were collected from patients with multiple myeloma, washed, and resuspended with 250 IU IU / mL IL-2 in T cell growth medium (TCGM). Pre- and post-wash cell counts, viability, and PBMC flow cytometry analysis were performed. Washed PBMCs were either cryopreserved until activation or used fresh. On day 0, T cells were activated and stimulated by culturing PBMCs with 250 IU IU / mL IL-2, 50 ng / mL anti-CD3 antibody, and 50 ng / mL anti-CD28 antibody in TCGM and cultured for approximately 18-24 hours. PBMC cultures were transduced with lentivirus encoding anti-BCMA CAR (e.g., SEQ ID NO:1, SEQ ID NO:2) for approximately 18-24 hours. PBMC cultures were then cultured for T cell expansion in TCGM containing 250 IU / mL IL-2 for 9 days (10-day manufacturing process). The expanded cells were harvested, washed, and cryopreserved in a controlled rate freezer at a temperature of at least -80°C, and subsequently stored in the vapor phase of a liquid nitrogen storage tank.

[0306] Frozen cells were subsequently thawed / washed / counted and tested for viability (>70% viability required). Cells were then used for CyTOF experiments or frozen as cell pellets stored in TRIzol for later RNA extraction and gene expression analysis.

[0307] EXPT.1. Cells were stained with metal-conjugated anti-human antibodies against T cell markers and analyzed using a Fluidigm CyTOF Helios Mass Cytometer. Protein marker expression was gated on a single marker basis compared to an established negative population in a reference sample spiked into each sample prior to antibody staining. Cells were classified into memory cell types using a combination of markers and gated on positive marker expression by the silhouette method. Memory populations of CD4 and CD8 T cells, respectively, were gated using the following combination of markers: T Naive (CCR7+CD45RO-CD95-), T SCM (CCR7+CD45RO-CD95+), T CM(CCR7+CD45RO+CD95+), T EM (CCR7-CD45RO+CD95+), T EF (CCR7-CD45RO-CD95+). Major immune populations were gated using the following marker combinations: CD4 T cells (CD3+CD4+CD8-CD14-CD19-CD56-), CD8 T cells (CD3+CD4-CD8+CD14-CD19-CD56-), NK cells (CD3-CD19-CD14-CD56+), NKT cells (CD3+CD56+CD19-CD14-), B cells (CD3-CD19+CD14-CD56-) and monocytes (CD3-CD19-CD14+CD56-). Differential abundance of cell proportions was inferred using a quasi-binomial generalized linear model adjusted for sex. Differences in the proportions of individual markers in each cell type were estimated using the Wilcoxon rank sum test. CAR T cell compositions were compared among patients with a duration of response greater than 18 months (sustained responders) compared to all patients with a duration of response less than 18 months (non-sustained responders). Figure 11A and Figure 11B.

[0308] EXPT 2. Cells were stained with metal-labeled anti-human antibodies against T cell markers, including LEF-1, and analyzed by CyTOF. CyTOF data was quality checked and analyzed to yield expression of individual markers for CD4 and CD8 immune cell populations. Differences in the proportions of individual markers in each cell type were estimated using Wilcoxon rank sum tests. Analysis of gene-level counts from formulation samples was performed using differential expression analysis in males vs. females and in sustained responders compared to non-sustained responders. Figure 12A.

[0309] For total RNA, RNA was extracted using phenol / chloroform extraction and Qiagen miRNA-easy kit, and rRNA was depleted using Kapa RNA HyperPrep kit with RiboErase. RNA quality / quantity was determined by Tapestation 2200 (RNA Integrity Number or RIN value >7 required). Sequencing libraries were prepared using Illumina TruSeq RNA Library Preparation Kit. Library quality and quantity were determined by Tapestation 2200 (DNA kit) and sequenced using Illumina NextSeq550 instrument. Sequencing data was analyzed. Correlation of LEF1 gene expression with serum BCMA (sBCMA) levels was determined using Spearman's rank correlation. Figure 12B.

[0310] Example 15 Anti-BCMA CAR T cell therapy PBMCs were collected from patients with multiple myeloma, washed, and resuspended in T cell growth medium (TCGM) with 250 IU / mL IL-2. Pre- and post-wash cell counts, viability, and PBMC flow cytometry analysis were performed. Washed PBMCs were either cryopreserved until activation or used fresh. On day 0, T cells were activated and stimulated by culturing PBMCs in TCGM with 250 IU / mL IL-2, 50 ng / mL anti-CD3 antibody, 50 ng / mL anti-CD28 antibody, and cultured in the presence of 1 M ZSTK474 (PI3K inhibitor, CAS NO. 475110-96-4) for approximately 18 to 24 hours. PBMC cultures were transduced with lentivirus encoding anti-BCMA CAR (e.g., SEQ ID NO. 1, SEQ ID NO. 2) for approximately 18 to 24 hours. PBMC cultures were then cultured for 9 days (10 day manufacturing process) in TCGM containing 250 IU / mL IL-2 and 1 μM ZSTK474 for T cell expansion. Expanded cells were harvested, washed, and cryopreserved in a controlled rate freezer at a temperature of at least −80° C., followed by storage in the vapor phase of a liquid nitrogen storage tank.

[0311] Cryopreserved samples were thawed and stained with metal-labeled anti-human antibodies against T cell markers including CD3, CD27, CCR7, and CD57. Labeled cells were analyzed using a Fluidigm CyTOF Helios Mass Cytometer. Manual analysis of CyTOF phenotypes was performed using the FlowJo software package. Protein marker expression was gated on a single marker basis based on an established negative population in a reference sample spiked into each subject's sample prior to antibody staining. The percentage of CD3+ live cells expressing CCR7 (Figure 13, top left panel), LEF1 (Figure 13, top center panel), and CD57 (Figure 13, top right panel) are shown between PBMCs and DPs. This indicated that the PI3-K inhibitor-based manufacturing process enriched for early memory, less differentiated cells.

[0312] The percentage of live CD3+ cells expressing CCR7 (Figure 13, bottom left panel), LEF-1 (Figure 13, bottom left center panel), and CD57 (Figure 13, bottom right panel) are shown on the y-axis. The maximum vector copy number (VCN) determined by PCR on CD3+ cells extracted from whole blood at various time points post-infusion is shown on the x-axis. These graphs show a positive correlation in the maximum expansion of anti-BCMA CAR+ cells post-infusion, and a negative correlation with the percentage of CD3+ DP cells expressing LEF-1, as well as the percentage of CD3+ DP expressing CD57. This indicates that enrichment of CCR7 and LEF-2 in DP leads to more robust expansion of anti-BCMA CAR in vivo.

[0313] The percentage of live CD3+ cells expressing CD57 (a marker of senescence), LEF-1, CCR7, and CD27 (memory cells) are shown as cluster heatmaps in Figure 14. Red indicates a relatively higher percentage of cells in the sample compared to other feeds of the marker. Blue indicates a relatively lower percentage of cells in the sample compared to other feeds of the marker. Data were grouped using average linkage hierarchical clustering, and the top three clusters, as determined by a dendrogram of the clusters, were associated with the patient's clinical response at 6 months (progressive or non-progressive disease). Only patients with available follow-up data to perform clinical assessment of response at 6 months were included in this analysis. Unsupervised clustering shows an association of high CD57 expression, low LEF-1 / CCR7 / CD27 expression group with progressors at 6 months (4 / 6 progressors), while the group with high LEF-1 / CCR7 / CD27 expression and low CD57 expression are mainly non-progressors (1 / 7 progressors). The intermediate group has 1 / 5 progressors. This indicates a correlation between memory and aging markers in the drug and sustained clinical response.

[0314] In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by this disclosure. In certain embodiments, for example, the following are provided: (Item 1) At least 10% CD27 + cGMP manufactured populations of anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells, including anti-BCMA CAR T cells. (Item 2) The population is characterized in that it contains at least 15% CD27 + 2. A cGMP manufactured population of anti-BCMA CAR T cells according to item 1, comprising anti-BCMA CAR T cells. (Item 3) The population is characterized in that it contains at least 20% CD27 + 2. A cGMP manufactured population of anti-BCMA CAR T cells according to item 1, comprising anti-BCMA CAR T cells. (Item 4) The population is characterized in that it contains at least 25% CD27 + 2. A cGMP manufactured population of anti-BCMA CAR T cells according to item 1, comprising anti-BCMA CAR T cells. (Item 5) The population is characterized in that it contains at least 30% CD27 + 2. A cGMP manufactured population of anti-BCMA CAR T cells according to item 1, comprising anti-BCMA CAR T cells. (Item 6) CD27 + Anti-BCMA CAR T cells are LEF1 + and / or CCR7 + and / or TCF1 + 6. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 5, which is an anti-BCMA CAR T cell. (Item 7) CD27 + Anti-BCMA CAR T cells are LEF1 + and CCR7 + and TCF1 + 6. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 5, which is an anti-BCMA CAR T cell. (Item 8) CD27 + Anti-BCMA CAR T cells increase CD4 + 6. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 5, comprising anti-BCMA CAR T cells. (Item 9) CD27 + Anti-BCMA CAR T cells are CD8 + 6. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 5, comprising anti-BCMA CAR T cells. (Item 10) CD27 + Anti-BCMA CAR T cells are CD4 + and CD8 + 6. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 5, comprising anti-BCMA CAR T cells. (Item 11) At least 10% LEF1 + and / or CCR7 + and TCF1 + cGMP manufactured population of anti-BCMA CAR T cells, including anti-BCMA CAR T cells. (Item 12) The population comprises at least 15% LEF1+ and / or CCR7 + and TCF1 + 12. A cGMP manufactured population of anti-BCMA CAR T cells according to item 11, comprising: (Item 13) The population comprises at least 20% LEF1 + and / or CCR7 + and TCF1 + 12. A cGMP manufactured population of anti-BCMA CAR T cells according to item 11, comprising: (Item 14) The population comprises at least 25% LEF1 + and / or CCR7 + and TCF1 + 12. A cGMP manufactured population of anti-BCMA CAR T cells according to item 11, comprising: (Item 15) The population comprises at least 30% LEF1 + and / or CCR7 + and TCF1 + 12. A cGMP manufactured population of anti-BCMA CAR T cells according to item 11, comprising: (Item 16) LEF1 + and / or CCR7 + and / or TCF1 + Anti-BCMA CAR T cells induce CD27 + 16. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 11 to 15, which is an anti-BCMA CAR T cell. (Item 17) LEF1 + and / or CCR7 + and / or TCF1 + Anti-BCMA CAR T cells are LEF1 + CCR7 + TCF1 + CD27 + 16. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 11 to 15, which is an anti-BCMA CAR T cell. (Item 18) The anti-BCMA CAR T cells are + 16. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 11 to 15, comprising anti-BCMA CAR T cells. (Item 19) The anti-BCMA CAR T cells are CD8 + 16. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 11 to 15, comprising anti-BCMA CAR T cells. (Item 20) The anti-BCMA CAR T cells are + and CD8 + 16. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 11 to 15, comprising anti-BCMA CAR T cells. (Item 21) 21. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 20, wherein the cells were produced from a subject with multiple myeloma or lymphoma. (Item 22) 22. The cGMP manufactured population of anti-BCMA CAR T cells of any one of items 1-21, wherein the cells were produced from a subject with relapsed / refractory multiple myeloma. (Item 23) 23. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 22, wherein the cells comprise a lentivirus comprising a polynucleotide encoding said anti-BCMA CAR. (Item 24) 24. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 23, wherein the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO:1. (Item 25) 25. A cGMP manufactured population of anti-BCMA CAR T cells according to any one of items 1 to 24, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2. (Item 26) 26. The cGMP manufactured population of anti-BCMA CAR T cells of any one of items 1 to 25, wherein the cells are autologous. (Item 27) 27. The cGMP manufactured population of anti-BCMA CAR T cells of any one of items 1 to 26, wherein the cells are cryopreserved. (Item 28) 28. The cGMP manufactured population of anti-BCMA CAR T cells of any one of items 1-27, wherein the cells are formulated for administration to a subject with multiple myeloma or lymphoma. (Item 29) 1. A human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell that has been contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, wherein gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5; or (ii) CCL1, NR4A2, ATF3, CCL5, WNT5B is at least 1.5-fold or at least 2-fold greater in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells that have been contacted ex vivo with the PI3K inhibitor for about 10 days. (Item 30) 1. A human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell that has been contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, wherein gene expression of one, two, three, four, five, six, seven, eight, nine, or all of: (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62; or (ii) NKD2 and NQO1 is at least 1.5-fold or at least 2-fold less in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells that have been contacted ex vivo with the PI3K inhibitor for about 10 days. (Item 31) 1. Human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells contacted ex vivo with a phosphatidyl-inositol-3 kinase (PI3K) inhibitor for about 5 to about 7 days, wherein the anti-BCMA CAR T cells are more potent than anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days. and (ii) gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, respectively, is at least 1.5-fold or at least 2-fold less in T cells and (i) gene expression of one, two, three, four, five, six, seven, eight, nine, or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1, respectively, is at least 1.5-fold or at least 2-fold less in human anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells. (Item 32) CD4 + 32. The human anti-BCMA CAR T cell of any one of items 29 to 31, wherein the anti-BCMA CAR T cell has a central memory T cell (TCM)-like phenotype. (Item 33) CD8 + 32. The human anti-BCMA CAR T cell of any one of items 29 to 31, wherein the anti-BCMA CAR T cell has a stem cell memory T cell (TSCM)-like phenotype. (Item 34) CD4 + Anti-BCMA CAR T cells have a TCM-like phenotype and are CD8 + anti-BCMA 32. The human anti-BCMA CAR T cell of any one of items 29 to 31, wherein the CAR T cell has a TSCM-like phenotype. (Item 35) 35. The human anti-BCMA CAR T cell of any one of items 29 to 34, wherein the cells are produced from a subject with multiple myeloma or lymphoma. (Item 36) 36. The human anti-BCMA CAR T cell of any one of items 29 to 35, wherein the cells produced from a subject having relapsed / refractory multiple myeloma. (Item 37) 37. The human anti-BCMA CAR T cell of any one of items 29 to 36, wherein the cell comprises a lentivirus comprising a polynucleotide encoding the anti-BCMA CAR. (Item 38) 38. The human anti-BCMA CAR T cell according to any one of items 29 to 37, wherein the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO: 1. (Item 39) 39. The human anti-BCMA CAR T cell of any one of items 29 to 38, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO: 2. (Item 40) 40. The human anti-BCMA CAR T cell of any one of items 29 to 39, wherein the cell is autologous. (Item 41) 41. The human anti-BCMA cell according to any one of items 29 to 40, wherein the cells are cryopreserved. CAR T cells. (Item 42) 42. The human anti-BCMA CAR T cell of any one of items 29 to 41, wherein the cells are formulated for administration to a subject with multiple myeloma or lymphoma. (Item 43) 43. The human anti-BCMA CAR T cell of any one of items 29 to 42, wherein the PI3K inhibitor is ZSTK474. (Item 44) A physiologically acceptable excipient and an anti-BCMA compound according to any one of items 29 to 43. and a therapeutically effective amount of a CAR T cell. (Item 45) The therapeutically effective amount of the anti-BCMA CAR T cells is at least about 5.0×10 7 45. The composition of claim 44, wherein the anti-BCMA CAR T cells. (Item 46) The therapeutically effective amount of the anti-BCMA CAR T cells is at least about 15.0×10 7 45. The composition of claim 44, wherein the anti-BCMA CAR T cells. (Item 47) The therapeutically effective amount is at least about 45.0×10 7 45. The composition of claim 44, wherein the anti-BCMA CAR T cells. (Item 48) The therapeutically effective amount is at least about 80.0×10 7 45. The composition of claim 44, wherein the anti-BCMA CAR T cells. (Item 49) 49. The composition of any one of items 44 to 48, formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10. (Item 50) A method of treating a subject having multiple myeloma or lymphoma with the composition according to any one of items 44 to 49. (Item 51) 51. The method of claim 50, wherein the subject has relapsed / refractory multiple myeloma. (Item 52) 1. A method of producing anti-BCMA CAR T cells, comprising: (a) activating a population of T cells and stimulating said population of T cells to proliferate; (b) transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1; (c) culturing and expanding the transduced T cells for about 5 to about 7 days; 20. A method of producing anti-BCMA CAR T cells, wherein steps (a)-(c) are performed in the presence of a PI3K inhibitor, and wherein gene expression of one, two, three, four, five, six, seven, eight, nine, ten or all of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5 and WNT5B is at least 1.5-fold or at least 2-fold greater in said cultured T cells of step (c) compared to T cells transduced and cultured and expanded according to step (b) for about 10 days. (Item 53) 1. A method of producing anti-BCMA CAR T cells, comprising: (a) activating a population of T cells and stimulating said population of T cells to proliferate; (b) transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1; (c) culturing and expanding the transduced T cells for about 5 to about 7 days; 20. A method of producing anti-BCMA CAR T cells, wherein steps (a)-(c) are performed in the presence of a PI3K inhibitor, and wherein gene expression of one, two, three, four, five, six, seven, eight, nine or all of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5-fold or at least 2-fold less in the cultured T cells of step (c) compared to T cells transduced and cultured and expanded according to step (b) for about 10 days. (Item 54) 1. A method of producing anti-BCMA CAR T cells, comprising: (a) activating a population of T cells and stimulating said population of T cells to proliferate; (b) transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1; (c) culturing and expanding the transduced T cells for about 5 to about 7 days; Steps (a) to (c) are carried out in the presence of a PI3K inhibitor; and (ii) one, two, three, four, five, six, seven, eight, nine, or ten of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5; or (ii) one, two, three, four, five, six, seven, eight, nine, or ten of: CCL1, NR4A2, ATF3, CCL5, and WNT5B, in the cultured T cells of step (c) compared to T cells transduced and cultured and expanded according to step (b) for about 10 days. , 10, or all of the gene expression is at least 1.5-fold or at least 2-fold greater and (i) one, two, three, four, five, six, seven, eight, nine, or all of the gene expression is at least 1.5-fold or at least 2-fold less for one, two, three, four, five, six, seven, eight, nine, or all of the following: (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2, and WDR62; or (ii) NKD2 and NQO1. A method for producing T cells. (Item 55) 1. A method of producing anti-BCMA CAR T cells, comprising: (a) activating a population of T cells and stimulating said population of T cells to proliferate; (b) transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO:1; (c) culturing and expanding the transduced T cells for about 5 to about 7 days; Steps (a) to (c) are carried out in the presence of a PI3K inhibitor, and the expanded cells are + and / or LEF1 + and / or CCR7 + and / or TCF1 + The method of producing anti-BCMA CAR T cells. (Item 56) The anti-BCMA CAR T cells express at least 10% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 56. The method of any one of items 52 to 55, comprising T cells. (Item 57) The anti-BCMA CAR T cells express at least 15% CD27+ and / or LEF1 + and / or CCR7 + and / or TCF1 + 56. The method of any one of items 52 to 55, comprising T cells. (Item 58) The anti-BCMA CAR T cells express at least 20% CD27 + and / or LEF1 + , and / or CCR7 + and / or TCF1 + 56. The method of any one of items 52 to 55, comprising T cells. (Item 59) The anti-BCMA CAR T cells express at least 25% CD27 + Cells and / or LEF1 + Cells and / or CCR7 + Cells and / or TCF1 + 56. The method of any one of items 52 to 55, comprising T cells. (Item 60) The anti-BCMA CAR T cells express at least 30% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 56. The method of any one of items 52 to 55, comprising T cells. (Item 61) CD27 + Cells expressing LEF1 + and / or CCR7 + and / or TCF1 + The method according to any one of Items 52 to 60, (Item 62) CD27 + Cells expressing LEF1 + and / or CCR7 + and TCF1 + The method according to any one of Items 52 to 60, (Item 63) CD27 + Anti-BCMA CAR T cells increase CD4 + 63. The method of any one of items 52 to 62, comprising anti-BCMA CAR T cells. (Item 64) CD27 + Anti-BCMA CAR T cells are CD8 + 63. The method of any one of items 52 to 62, comprising anti-BCMA CAR T cells. (Item 65) CD27 + Anti-BCMA CAR T cells increase CD4 + and CD8 + 63. The method of any one of items 52 to 62, comprising anti-BCMA CAR T cells. (Item 66) 66. The method of any one of items 52 to 65, wherein the T cells are autologous. (Item 67) 67. The method of any one of items 52 to 66, wherein the method further comprises isolating peripheral blood mononuclear cells (PBMCs) as a source of the T cells. (Item 68) 68. The method of claim 67, wherein the PBMCs are isolated from a subject with multiple myeloma or lymphoma. (Item 69) 69. The method of claim 68, wherein the subject has relapsed / refractory multiple myeloma. (Item 70) 70. The method according to any one of items 52 to 69, wherein the method further comprises cryopreserving the PBMCs prior to step (a). (Item 71) 71. The method according to any one of items 52 to 70, wherein the T cells are cryopreserved after step (c). (Item 72) 72. The method according to any one of items 52 to 71, wherein the T cells are activated and stimulated to proliferate for about 18 to about 24 hours. (Item 73) 73. The method of any one of items 52 to 72, wherein the activation of the T cells comprises contacting the T cells with an anti-CD3 antibody or an antigen-binding fragment thereof. (Item 74) 74. The method of claim 73, wherein the anti-CD3 antibody or antigen-binding fragment thereof is soluble. (Item 75) 74. The method of claim 73, wherein the anti-CD3 antibody or antigen-binding fragment thereof is bound to a surface. (Item 76) 76. The method of claim 75, wherein the surface is a bead, optionally a paramagnetic bead. (Item 77) 77. The method of any one of items 52 to 76, wherein stimulating the T cells comprises contacting the T cells with an anti-CD28 antibody or antigen-binding fragment thereof. (Item 78) 78. The method of claim 77, wherein the anti-CD28 antibody or antigen-binding fragment thereof is soluble. (Item 79) 78. The method of claim 77, wherein the anti-CD28 antibody or antigen-binding fragment thereof is bound to a surface. (Item 80) 80. The method of claim 79, wherein the surface is a bead, optionally a paramagnetic bead, optionally the paramagnetic bead is bound to the anti-CD3 antibody or antigen-binding fragment thereof. (Item 81) 81. The method according to any one of items 52 to 80, wherein the cells are transduced with an HIV-1 derived lentiviral vector. (Item 82) 82. The method of any one of items 52 to 81, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2. (Item 83) 83. The method according to any one of items 52 to 82, wherein the PI3K inhibitor is ZSTK474. (Item 84) In adoptive cell therapy, CD4 + TCM-like anti-BCMA CAR T cells and CD8 + 1. A method for expanding TSCM-like anti-BCMA CAR T cells, comprising ex vivo contacting anti-BCMA CAR T cells with a PI3K inhibitor for about 5 to about 7 days, + TCM-like anti-BCMA CAR T cells and CD8 + The method, wherein the number of TSCM-like anti-BCMA CAR T cells is at least two-fold greater in the anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days. (Item 85) The anti-BCMA CAR T cells express at least 10% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 85. The method of item 84, comprising T cells. (Item 86) The anti-BCMA CAR T cells express at least 15% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + The method of claim 84 or 85, comprising T cells. (Item 87) The anti-BCMA CAR T cells express at least 20% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 87. The method of any one of items 84 to 86, comprising T cells. (Item 88) The anti-BCMA CAR T cells express at least 25% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 88. The method of any one of items 84 to 87, comprising T cells. (Item 89) The anti-BCMA CAR T cells express at least 30% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + 89. The method of any one of items 84 to 88, comprising T cells. (Item 90) 90. The method of any one of items 84 to 89, wherein the T cells are autologous. (Item 91) 91. The method of any one of items 84 to 90, wherein the method further comprises isolating peripheral blood mononuclear cells (PBMCs) as a source of the T cells. (Item 92) 92. The method of claim 91, wherein the PBMCs are isolated from a subject with multiple myeloma or lymphoma. (Item 93) 93. The method of claim 92, wherein the subject has relapsed / refractory multiple myeloma. (Item 94) 94. The method of any one of items 84 to 93, wherein the anti-BCMA CAR T cells comprise an HIV-1 derived lentiviral vector. (Item 95) 95. The method of any one of items 84 to 94, wherein the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO: 1. (Item 96) 96. The method of any one of items 84 to 95, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:2. (Item 97) 84. A pharmaceutical composition comprising a pharma- ceutical acceptable excipient and a therapeutically effective amount of the anti-BCMA CAR T cells according to the method of any one of items 52 to 83. (Item 98) A pharma- ceutically acceptable excipient and a CD4 + TCM anti-BCMA CAR T cells and CD8 + A pharmaceutical composition comprising a therapeutically effective amount of TSCM anti-BCMA CAR T cells. (Item 99) A method of treating a subject having multiple myeloma or lymphoma with the composition of item 97 or item 98. (Item 100) 100. The method of claim 99, wherein the subject has relapsed / refractory multiple myeloma. (Item 101) 1. A method of increasing gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5 and WNT5B in an anti-BCMA CAR T cell, comprising contacting the anti-BCMA CAR T cell with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein said gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5 and WNT5B is at least 1.5 fold greater in said anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with said PI3K inhibitor for about 10 days. (Item 102) 1. A method of reducing gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 in anti-BCMA CAR T cells, comprising contacting anti-BCMA CAR T cells with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein said gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5 fold less in said anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with said PI3K inhibitor for about 10 days. (Item 103) 1. A method of increasing gene expression of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, respectively, and decreasing gene expression of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1, respectively, in anti-BCMA CAR T cells, the method comprising contacting anti-BCMA CAR T cells ex vivo with a PI3K inhibitor for about 5 to about 7 days, wherein the anti-BCMA CAR T cells are more sensitive to the expression of the PI3K inhibitor than anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days. The method of claim 1, wherein the gene expression of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B is at least 1.5-fold greater and the gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1 is at least 1.5-fold less in T cells. (Item 104) 1. A method of increasing the therapeutic efficacy of an anti-BCMA CAR T cell, comprising contacting an anti-BCMA CAR T cell with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein said increase in therapeutic efficacy is indicated by an increase in gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B that is at least 1.5 fold greater in said anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with said PI3K inhibitor for about 10 days. (Item 105) 1. A method of increasing the therapeutic efficacy of an anti-BCMA CAR T cell, comprising contacting an anti-BCMA CAR T cell with a PI3K inhibitor ex vivo for about 5 to about 7 days, wherein said increase in therapeutic efficacy is indicated by a decrease in gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR 22, ILDR2, ATAD3, NKD2 and WDR62, or (ii) NKD2 and NQO1 that is at least 1.5 fold less in said anti-BCMA CAR T cells than in anti-BCMA CAR T cells contacted ex vivo with said PI3K inhibitor for about 10 days. (Item 106) 1. A method of increasing the therapeutic efficacy of anti-BCMA CAR T cells, comprising ex vivo contacting anti-BCMA CAR T cells with a PI3K inhibitor for about 5 to about 7 days, wherein said increase in therapeutic efficacy is greater for anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor for about 10 days than for anti-BCMA CAR T cells contacted ex vivo with the PI3K inhibitor. and (ii) at least a 1.5-fold increase in gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of each of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5, or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B, and a 1.5-fold decrease in gene expression of each of (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2, and WDR62, or (ii) NKD2 and NQO1, in T cells. (Item 107) 107. The method of any one of items 101 to 106, wherein the anti-BCMA CAR T cells are from a subject with multiple myeloma or lymphoma. (Item 108) 108. The method of any one of items 101-107, wherein the anti-BCMA CAR T cells are from a subject with relapsed / refractory multiple myeloma. (Item 109) 109. The method of any one of items 101 to 108, wherein the anti-BCMA CAR T cells comprise an HIV-1 derived lentiviral vector comprising a polynucleotide encoding the anti-BCMA CAR. (Item 110) 100. The method of any one of items 101 to 109, wherein the anti-BCMA CAR comprises the amino acid sequence set forth in SEQ ID NO: 1. (Item 111) 111. The method of any one of items 101 to 110, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO: 2. (Item 112) 112. The method of any one of items 101-111, wherein the anti-BCMA CAR T cells are autologous. (Item 113) 13. The method according to any one of items 101 to 112, wherein the PI3K inhibitor is ZSTK474.

Claims

1. 1. A method for producing anti-BCMA CAR T cells, comprising: (a) activating a population of T cells and stimulating said population of T cells to proliferate; (b) transducing the T cells with a lentiviral vector encoding an anti-BCMA CAR comprising the amino acid sequence set forth in SEQ ID NO: 1; (c) expanding the transduced T cells in culture for 5 to 7 days; Steps (a)-(c) are carried out in the presence of a PI3K inhibitor, wherein: (I) in the cultured T cells of step (c), compared to anti-BCMA CAR T cells produced in the presence of a PI3K inhibitor according to steps (a) to (b) and cultured for 10 days following step (b), at least 1.5-fold greater gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5 or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B; (II) in the cultured T cells of step (c), compared to anti-BCMA CAR T cells produced in the presence of a PI3K inhibitor according to steps (a) to (b) and cultured for 10 days following step (b), (i) gene expression of one, two, three, four, five, six, seven, eight, nine or all of NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2 and WDR62 or (ii) NKD2 and NQO1 is at least 1.5-fold less; or (III) in the cultured T cells of step (c), compared to anti-BCMA CAR T cells produced in the presence of a PI3K inhibitor according to steps (a) to (b) and cultured for 10 days following step (b), 1. A method of producing anti-BCMA CAR T cells having at least 1.5-fold greater gene expression of one, two, three, four, five, six, seven, eight, nine, ten, or all of: (i) NR4A2, LY9, LIN7A, WNT5B, BCL6, EGR1, EGR2, ATF3, CCL1, IL-1A, and CCL5; or (ii) CCL1, NR4A2, ATF3, CCL5, and WNT5B; and at least 1.5-fold less gene expression of one, two, three, four, five, six, seven, eight, nine, or all of: (i) NQO1, CCNA1, IL17F, EMP1, SNHG19, PRR22, ILDR2, ATAD3, NKD2, and WDR62; or (ii) NKD2 and NQO1.

2. the anti-BCMA CAR T cells (i) at least 10% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + T cells; (ii) at least 15% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + T cells; (iii) at least 20% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + T cells; (iv) at least 25% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + T cells; or (v) at least 30% CD27 + and / or LEF1 + and / or CCR7 + and / or TCF1 + T cell The method of claim 1 , comprising:

3. CD27 + The cells are: (i) LEF1 + and / or CCR7 + and / or TCF1 + or (ii) LEF1 + and / or CCR7 + and TCF1 + The method of claim 2, wherein

4. CD27 + The anti-BCMA CAR T cells are: (i) CD4 + Anti-BCMA CAR T cells; (ii) CD8 + anti-BCMA CAR T cells; or (iii) CD4 + and CD8 + The method of claim 2 or 3, comprising anti-BCMA CAR T cells.

5. The method of any one of claims 1 to 4, wherein the T cells are autologous T cells.

6. 6. The method of any one of claims 1 to 5, wherein isolated peripheral blood mononuclear cells (PBMCs) are the source of the T cells, and optionally the isolated PBMCs are from a subject with multiple myeloma or lymphoma, and further optionally the subject has relapsed / refractory multiple myeloma.

7. 7. The method of claim 6, wherein the method comprises cryopreserving the PBMCs prior to step (a).

8. The method of any one of claims 1 to 7, wherein the T cells are cryopreserved after step (c).

9. 9. The method of any one of claims 1 to 8, wherein the T cells are activated and stimulated to proliferate for 18 to 24 hours, optionally wherein activating the T cells comprises contacting the T cells with an anti-CD3 antibody or antigen-binding fragment thereof, optionally wherein the anti-CD3 antibody or antigen-binding fragment thereof is soluble or wherein the anti-CD3 antibody or antigen-binding fragment thereof is bound to a surface, and further optionally wherein the surface is a bead, optionally a paramagnetic bead.

10. 10. The method of any one of claims 1 to 9, wherein stimulating the T cells comprises contacting the T cells with an anti-CD28 antibody or antigen-binding fragment thereof, optionally wherein the anti-CD28 antibody or antigen-binding fragment thereof is soluble or wherein the anti-CD28 antibody or antigen-binding fragment thereof is bound to a surface, and further optionally wherein the surface is a bead, optionally a paramagnetic bead, optionally wherein the paramagnetic bead is bound to the anti-CD3 antibody or antigen-binding fragment thereof.

11. The method of any one of claims 1 to 10, wherein the cells are transduced with an HIV-1 derived lentiviral vector.

12. The method of any one of claims 1 to 11, wherein the anti-BCMA CAR is encoded by the polynucleotide sequence set forth in SEQ ID NO:

2.

13. The method of any one of claims 1 to 12, wherein the PI3K inhibitor is ZSTK474.

Citation Information

Patent Citations

  • Improved T cell composition

    JP2017518052A

  • BCMA chimeric antigen receptor

    JP2017538710A